SAMPLE	DISEASES	CTYPE	SAMPLE_ALTERATION	ALTERATION_MATCH	CTYPE_MATCH	DRUGS	BIOMARKER	RESPONSE	BIOMARKER_IDX	RESISTANCE_LIST	RESISTANCE_TYPE	EVIDENCE_LABEL	SOURCE	SOURCE_DETAILS
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Neratinib (ERBB2 inhibitor) + Capecitabine (Chemotherapy)	ERBB2 amplification	Responsive	2			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab (ERBB2 inhibitor)+ Trastuzumab (ERBB2 inhibitor) + Docetaxel (Chemotherapy)	ERBB2 amplification	Responsive	3			A	cgi	PMID:23801166
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Docetaxel (Chemotherapy)	ERBB2 overexpression	Responsive	4			A	cgi	PMID:23801166
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib (ERBB2 inhibitor) + Letrozole (Hormone therapy)	ERBB2 amplification	Responsive	5			A	cgi	FDA;PMID:19786658
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Fulvestrant (Estrogen receptor antagonist) + Palbociclib (CDK4/6 inhibitor)	ERBB2 expression -	Responsive	6			A	cgi	PMID:27407089
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Margetuximab (ERBB2 inhibitor) 	ERBB2 amplification	Responsive	7			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Margetuximab (ERBB2 inhibitor) 	ERBB2 overexpression	Responsive	8			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Tucatinib (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Capecitabine (chemotherapy)	ERBB2 amplification	Responsive	9			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Midostaurin (Pan-TK inhibitor)	FLT3-ITD	Responsive	16			A	cgi	FDA:https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia;PMID:28644114
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Gilteritinib (Kinase inhibitor )	FLT3 (D835,I836)	Responsive	17			A	cgi	FDA: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Gilteritinib (Kinase inhibitor )	FLT3-ITD	Responsive	18			A	cgi	FDA:https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation;PMID:31665578
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Midostaurin (Pan-TK inhibitor)	FLT3 (D835,I836)	Responsive	19			A	cgi	FDA:https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia; PMID:28644114
input01	Thyroid medullary	THM	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Pralsetinib (Tyrosine kinase inhibitor)	RET fusion	Responsive	26			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-ret-altered-thyroid-cancers;ASCO 2020 (abstr 109)
input01	Thyroid medullary	THM	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Selpercatinib (RET kinase inhibitor)	RET fusion	Responsive	27			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions;ASCO 2020 (abstr 3594)
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Cabozantinib (Kinase inhibitor )	RET fusion	Responsive	28			C	cgi	PMID:27825636
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Trametinib (MEK inhibitor) + Dabrafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	29			A	cgi	NCCN Non-Small Cell Lung Cancer guidlines 2022; FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	complete	YES	Lorlatinib (ALK inhibitor)	ALK oncogenic mutation	Responsive	37			A	cgi	FDA: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf 
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Encorafenib (BRAF inhibitor) + Cetuximab (EGFR mAb inhibitor)	BRAF (V600E)	Responsive	52			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation;PMID:31566309
input01	Stomach, Gastroesophageal junction adenocarcinoma	ST, GEJA	ERBB2 MUT* (G776A)	only gene	YES	Pembrolizumab (PD-1 blocking antibody) + Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	53			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120
input01	Stomach, Gastroesophageal junction adenocarcinoma	ST, GEJA	ERBB2 MUT* (G776A)	only gene	YES	Pembrolizumab (PD-1 blocking antibody) + Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 overexpression	Responsive	54			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer;PMID:34912120
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Ripretinib (Kinase inhibitor)	KIT (Y823D,N822,C809G,D820,A829P,D816,T670I)	Responsive	57			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor;PMID:32511981
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Neratinib (ERBB2 inhibitor) + Capecitabine (Chemotherapy)	ERBB2 overexpression	Responsive	74			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer;PMID:30860945
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib (ERBB2 inhibitor) + Letrozole (Hormone therapy)	ERBB2 overexpression	Responsive	75			A	cgi	FDA;PMID:19786658
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Tucatinib (ERBB2 inhibitor) + Trastuzumab (ERBB2 inhibitor) + Capecitabine (chemotherapy)	ERBB2 overexpression	Responsive	76			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer;PMID:31825569
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Pralsetinib (Tyrosine kinase inhibitor)	RET fusion	Responsive	77			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Selpercatinib (RET kinase inhibitor)	RET fusion	Responsive	78			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions
input01	Stomach, Gastroesophageal junction adenocarcinoma	ST, GEJA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab deruxtecan-nxki (Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	ERBB2 amplification	Responsive	85			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas
input01	Stomach, Gastroesophageal junction adenocarcinoma	ST, GEJA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab deruxtecan-nxki (Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	ERBB2 overexpression	Responsive	86			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas
input01	Non-small cell lung	NSCLC	ERBB2 MUT* (G776A)	only alteration type	YES	Trastuzumab deruxtecan-nxki (Antibody-drug conjugate: ERBB2 mAb inhibitor + topoisomerase I inhibitor)	ERBB2 oncogenic mutation	Responsive	87			A	cgi	FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung
input01	Colorectal adenocarcinoma	COREAD	ARAF MUT (S217F)	complete	YES	BRAF inhibitor + EGFR mAb inhibitors	ARAF oncogenic mutation	Resistant	92			CASE REPORT	cgi	ENA 2014 (abstr 428)
input01	Colorectal adenocarcinoma	COREAD	ARAF MUT (S217F)	complete	YES	BRAF inhibitor + MEK inhibitors	ARAF oncogenic mutation	Resistant	97			CASE REPORT	cgi	ENA 2014 (abstr 428)
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	complete	YES	EGFR TK inhibitors	BRAF (V600E,G469A)	Resistant	110			CASE REPORT	cgi	PMID:22773810
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	ALK inhibitor + IGF1R inhibitors	ALK fusion	Responsive	117			D	cgi	PMID:25173427
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	ALK inhibitor + MEK inhibitors	ALK fusion	Responsive	118			D	cgi	PMID:26301689
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	ALK inhibitor + SRC inhibitors	ALK fusion	Responsive	119			D	cgi	PMID:25394791
input01	Colorectal adenocarcinoma	COREAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	ALK inhibitors	ALK fusion	Responsive	120			CASE REPORT	cgi	PMID:26633560
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	HSP90 inhibitors	ALK fusion	Responsive	121			C	cgi	PMID:23553849
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	novel ALK inhibitors	ALK fusion	Responsive	122			C	cgi	PMID:23639470
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	novel ALK inhibitors	ALK (F1174L)	Responsive	123			D	cgi	PMID:24327273
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Alectinib (ALK inhibitor)	ALK fusion	Responsive	124	399	Resistant	A	cgi	FDA
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Alectinib (ALK inhibitor)	ALK fusion	Responsive	125	399	Resistant	A	cgi	FDA
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Brigatinib (Pan-TK inhibitor)	ALK amplification	Responsive	127			CASE REPORT	cgi	ASCO 2017 (abstr 9065)
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Brigatinib (Pan-TK inhibitor)	ALK (E1408V)	Responsive	128			CASE REPORT	cgi	ASCO 2017 (abstr 9065)
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Brigatinib (Pan-TK inhibitor)	ALK (L1196M)	Responsive	129			CASE REPORT	cgi	ASCO 2017 (abstr 9065)
input01	Non-small cell lung, Lung adenocarcinoma	NSCLC, LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Ceritinib (ALK inhibitor)	ALK fusion	Responsive	130			A	cgi	FDA
input01	Colorectal adenocarcinoma, Inflammatory myofibroblastic	COREAD, IM	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Ceritinib (ALK inhibitor)	ALK fusion	Responsive	131			CASE REPORT	cgi	PMID:26633560;PMID:26933125;PMID:27742657
input01	Hematologic malignancies	HEMATO	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Ceritinib (ALK inhibitor)	ALK fusion	Responsive	132			C	cgi	NCT02186821
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Ceritinib (ALK inhibitor)	ALK inframe insertion (1151T)	Responsive	133			A	cgi	PMID:24670165
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Ceritinib (ALK inhibitor)	ALK (L1196M,S1206Y,G1269A,I1171T)	Responsive	135			A	cgi	PMID:24670165;PMID:24327273
input01	Lymphoma, Glioblastoma	LY, GB	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib (ALK inhibitor)	ALK fusion	Responsive	136	650	Resistant	C	cgi	PMID:24491302;NCT02270034
input01	Non-small cell lung, Lung adenocarcinoma	NSCLC, LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib (ALK inhibitor)	ALK fusion	Responsive	137	650	Resistant	A	cgi	FDA
input01	Inflammatory myofibroblastic, Thyroid carcinoma	IM, THCA	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib (ALK inhibitor)	ALK fusion	Responsive	138	650	Resistant	CASE REPORT	cgi	PMID:20979472;PMID:24687827
input01	Acute myeloid leukemia	AML	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib (ALK inhibitor)	ALK (F856S,A348D)	Responsive	145	650	Resistant	D	cgi	PMID:26032424
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib (ALK inhibitor)	ALK (L1198F)	Responsive	147	650	Resistant	CASE REPORT	cgi	PMID:26698910
input01	Glioma	G	ALK MUT (F1245C)	complete	YES	Crizotinib (ALK inhibitor)	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Responsive	148	650	Resistant	D	cgi	PMID:22072639
input01	Colorectal adenocarcinoma	COREAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Entrectinib (Pan-TK inhibitor)	ALK fusion	Responsive	149			CASE REPORT	cgi	PMID:26633560;PMID:26933125
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Lorlatinib (ALK&ROS1 inhibitor)	ALK fusion	Responsive	150			C	cgi	PMID:26951079
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Brigatinib (Pan-TK inhibitor)	ALK fusion	Responsive	151			A	cgi	FDA
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Lorlatinib (ALK&ROS1 inhibitor)	ALK (C1156Y)	Responsive	152			D	cgi	PMID:27401242
input01	Colorectal adenocarcinoma	COREAD	APC MUT* (KIGT1310-1313X)	only alteration type	YES	Tankyrase inhibitors	APC oncogenic mutation	Responsive	153			D	cgi	PMID:22440753;PMID:23539443
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	only gene	YES	AR inhibitor next gens	AR amplification	Responsive	157			D	cgi	PMID:23589709;PMID:21859989
input01	Breast adenocarcinoma	BRCA	AR MUT (F877L)	only gene	YES	AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)	AR overexpression	Responsive	158			C	cgi	ASCO 2015 (abstr 1003)
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only gene	YES	EGFR inhibitors	ERBB2 amplification	Resistant	159			D	cgi	PMID:22956644
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	EGFR mAb inhibitors	ERBB2 amplification	Resistant	160			C	cgi	PMID:22586653;PMID:23348520
input01	Colorectal adenocarcinoma	COREAD	ERBB3 MUT (V104M)	only gene	YES	EGFR mAb inhibitors	ERBB3 amplification	Resistant	161			C	cgi	PMID:25520391
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	ESR1 inhibitors	ESR1-YAP1 fusion	Resistant	162			D	cgi	PMID:24055055
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	only gene	YES	Enzalutamide (AR inhibitor)	AR overexpression	Responsive	163	707	Resistant	C	cgi	PMID:24882673
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L), AR MUT (F877L)	only alteration type	YES	Enzalutamide (AR inhibitor)	AR (F877L) + AR (T878A)	Responsive	165	707	Resistant	D	cgi	PMID:27196756
input01	Lung adenocarcinoma	LUAD	ARAF MUT (S217F)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	ARAF (S214C)	Responsive	168	627	Resistant	CASE REPORT	cgi	http://www.jci.org/articles/view/72763;PMID:24569458
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitor + CDK2/4 inhibitors	BRAF (V600E)	Responsive	204	92	Resistant	D	cgi	PMID:22997239
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitor + EGFR mAb inhibitor +/- PI3K inhibitors	BRAF (V600)	Responsive	205	92	Resistant	C	cgi	PMID:28363909
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitor + HSP90 inhibitors	BRAF (V600E)	Responsive	206	92	Resistant	D	cgi	PMID:22351686
input01	Thyroid	TH	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitor + MEK inhibitors	BRAF (V600E)	Responsive	207	92	Resistant	C	cgi	ASCO 2013 (abstr 9029)
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	only gene	YES	BRAF inhibitor + MEK inhibitors	BRAF fusion	Responsive	208	92	Resistant	CASE REPORT	cgi	ASCO 2017 (abstr 9072)
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitor + PI3K pathway inhibitors	BRAF (V600E)	Responsive	209	92	Resistant	D	cgi	PMID:22389471;PMID:21156289
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitors	BRAF (L597R)	Responsive	210	92	Resistant	CASE REPORT	cgi	PMID:23715574
input01	Glioma	G	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitors	BRAF (V600E)	Responsive	211	92	Resistant	D	cgi	PMID:22038996;PMID:22586120
input01	Ovary	OV	BRAF MUT (G469A)	only alteration type	YES	BRAF inhibitors	BRAF (V600E)	Responsive	212	92	Resistant	CASE REPORT	cgi	PMID:22608338
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	ERK inhibitors	BRAF (V600E)	Responsive	214			D	cgi	PMID:23614898;PMID:22997239
input01	Head an neck squamous	HNSC	BRAF MUT (G469A)	complete	YES	ERK inhibitors	BRAF (G469A)	Responsive	215			CASE REPORT	cgi	ASCO 2017 (abstr 2508)
input01	Billiary tract	BT	BRAF MUT (G469A)	only alteration type	YES	ERK inhibitors	BRAF (L485W)	Responsive	216			CASE REPORT	cgi	ASCO 2017 (abstr 2508)
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	only alteration type	YES	ERK inhibitors	BRAF (V600E)	Responsive	217			C	cgi	ASCO 2017 (abstr 2508)
input01	Thyroid	TH	BRAF MUT (G469A)	only alteration type	YES	MEK inhibitors	BRAF (V600E)	Responsive	218	427	Resistant	C	cgi	PMID:22241789
input01	Ovary	OV	BRAF MUT (G469A)	only alteration type	YES	MEK inhibitors	BRAF (V600E)	Responsive	219	427	Resistant	D	cgi	PMID:19018267
input01	Any cancer type	CANCER	BRAF MUT (G469A)	only alteration type	YES	Pan-RAF inhibitors	BRAF inframe deletion (L485),inframe deletion (P490)	Responsive	220			D	cgi	PMID:26732095
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Pan-RAF inhibitors	BRAF (V600E)	Responsive	221			C	cgi	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005);AACR 2017 (abstr  CT002)
input01	Lung adenocarcinoma, Cutaneous melanoma, Prostate adenocarcinoma	LUAD, CM, PRAD	BRAF MUT (G469A)	only gene	YES	MEK inhibitors (Trametinib,etc)	BRAF fusion	Responsive	222	427	Resistant	D	cgi	PMID:24727320;PMID:24345920;PMID:20526349
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	MEK inhibitors (Trametinib,etc)	BRAF (K601R,L597R,V600R)	Responsive	223	427	Resistant	CASE REPORT	cgi	PMID:23248257;PMID:22805292;PMID:23248257
input01	Lung adenocarcinoma, Thyroid	LUAD, TH	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	225	92	Resistant	C	cgi	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	226	92	Resistant	A	cgi	NCCN
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	227	92	Resistant	A	cgi	FDA
input01	Gastrointestinal stromal	GIST	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	228	92	Resistant	CASE REPORT	cgi	PMID:23470635;PMID:22608338
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib (BRAF inhibitor)	BRAF (V600R)	Responsive	229	92	Resistant	C	cgi	PMID:23237741
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	BRAF (V600E)	Responsive	230			C	cgi	PMID:26392102;ASCO 2015 (abstr 8006)
input01	Neuroendocrine	NEU	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	BRAF (V600E)	Responsive	231			CASE REPORT	cgi	PMID:27048246
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	BRAF (V600E)	Responsive	232			A	cgi	PMID:27283860
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	BRAF (V600E,V600K)	Responsive	233			A	cgi	FDA
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	BRAF (G466V)	Responsive	234			D	cgi	PMID:22649091
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	BRAF (Y472C)	Responsive	235			CASE REPORT	cgi	PMID:22649091
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Irinotecan + Vemurafenib + Cetuximab (TOPO1 inhibitor + BRAF inhibitor + EGFR mAb inhibitor)	BRAF (V600)	Responsive	236			C	cgi	PMID:27729313
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	BRAF (V600)	Responsive	238			C	cgi	ENA 2014 (abstr 11LBA)
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	BRAF (V600E)	Responsive	239			C	cgi	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)
input01	Malignant astrocytoma	MA	BRAF MUT (G469A)	only alteration type	YES	PLX4720 (BRAF inhibitor)	BRAF (V600E)	Responsive	240	92	Resistant	D	cgi	PMC3638050
input01	Ovary	OV	BRAF MUT (G469A)	only gene	YES	Selumetinib (MEK inhibitor)	BRAF fusion	Responsive	241	427	Resistant	CASE REPORT	cgi	PMID:26324360
input01	Pediatric glioma	PG	BRAF MUT (G469A)	only alteration type	YES	Selumetinib (MEK inhibitor)	BRAF (V600E)	Responsive	242	427	Resistant	C	cgi	NCT01089101
input01	Cutaneous melanoma, Lung adenocarcinoma, Prostate adenocarcinoma	CM, LUAD, PRAD	BRAF MUT (G469A)	only gene	YES	Sorafenib (Pan-TK inhibitor)	BRAF fusion	Responsive	243	627	Resistant	D	cgi	PMID:238900088;PMID:20526349;PMID:24727320
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	BRAF (D594G,G469E)	Responsive	244	627	Resistant	D	cgi	PMID:18794803
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Trametinib (MEK inhibitor)	BRAF (V600E,V600K)	Responsive	245	427	Resistant	A	cgi	FDA
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600D,V600K,V600M,V600G,V600R)	Responsive	248	92	Resistant	A	cgi	NCCN
input01	Lung adenocarcinoma, Hairy-Cell leukemia, Myeloma	LUAD, HCL, MYMA	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	249	92	Resistant	CASE REPORT	cgi	PMID:22743296;PMID:22621641;PMID:23612012
input01	Malignant astrocytoma	MA	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	250	92	Resistant	C	cgi	PMID:22586120
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	251	92	Resistant	A	cgi	FDA
input01	Thyroid carcinoma	THCA	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600E)	Responsive	252	92	Resistant	C	cgi	PMID:22608338;PMID:20818844;PMID:23489023
input01	Non-small cell lung, Lagerhans cell histiocytosis, Erdheim-Chester histiocytosis	NSCLC, HISLC, HISEC	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	Responsive	253	92	Resistant	A	cgi	PMID:26287849
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	BRAF (V600E,V600K)	Responsive	254			A	cgi	FDA
input01	Prostate adenocarcinoma	PRAD	CHEK2 MUT (V438F)	complete	YES	Olaparib (PARP inhibitor)	CHEK2 oncogenic mutation	Responsive	321			A	cgi	PMID:26510020;AACR 2015 (abstr CT322);FDA:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer;PMID:32343890
input01	Prostate adenocarcinoma	PRAD	CHEK2 MUT (V438F)	only gene	YES	Olaparib (PARP inhibitor)	CHEK2 deletion	Responsive	322			C	cgi	AACR 2015 (abstr CT322)
input01	Myelodisplasic proliferative syndrome	MDPS	CSF1R MUT (Y969*)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	CSF1R (Y571D)	Responsive	331			D	cgi	PMID:18971950
input01	Colorectal adenocarcinoma	COREAD	PTEN MUT (R335*)	complete	YES	EGFR mAb inhibitors	PTEN oncogenic mutation	Resistant	409			B	cgi	PMID:21163703;PMID:19398573
input01	Colorectal adenocarcinoma	COREAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	EGFR mAb inhibitors	PTEN deletion	Resistant	410			B	cgi	PMID:21163703;PMID:19398573
input01	Endometrium	ED	PTEN MUT (R335*)	complete	YES	MTOR inhibitors	PTEN oncogenic mutation	No Responsive	411			C	cgi	PMID:21788564;PMID:23238879
input01	Endometrium	ED	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	MTOR inhibitors	PTEN deletion	No Responsive	414			C	cgi	PMID:21788564;PMID:23238879
input01	Cutaneous melanoma	CM	PTEN MUT (R335*), BRAF MUT (G469A)	complete	YES	BRAF inhibitors	PTEN oncogenic mutation + BRAF oncogenic mutation	Resistant	415			C	cgi	http://ascopubs.org/doi/abs/10.1200/PO.16.00054
input01	Cutaneous melanoma	CM	PTEN MUT* (K267X), PTEN MUT (R335*), BRAF MUT (G469A)	only gene	YES	BRAF inhibitors	PTEN deletion + BRAF oncogenic mutation	Resistant	418			C	cgi	http://ascopubs.org/doi/abs/10.1200/PO.16.00054
input01	Cutaneous melanoma	CM	PTEN MUT (R335*), BRAF MUT (G469A)	complete	YES	MEK inhibitors	PTEN oncogenic mutation + BRAF oncogenic mutation	Resistant	427			D	cgi	PMID:23039341
input01	Cutaneous melanoma	CM	PTEN MUT* (K267X), PTEN MUT (R335*), BRAF MUT (G469A)	only gene	YES	MEK inhibitors	PTEN deletion + BRAF oncogenic mutation	Resistant	428			D	cgi	PMID:23039341
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	ERBB2 inhibitor + CDK4/6 inhibitors	ERBB2 amplification	Responsive	429			D	cgi	PMID:26977878
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	ERBB2 inhibitors (Afatinib,Lapatinib,Neratinib,etc)	ERBB2 proximal exon 20	Responsive	430			C	cgi	PMID:26598547
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	ERBB2 mAb inhibitors (Trastuzumab,etc)	ERBB2 proximal exon 20	Responsive	431			C	cgi	PMID:26598547
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)	ERBB2 amplification	Responsive	432	409	Resistant	A	cgi	FDA
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	ERBB2 overexpression	Responsive	433			A	cgi	FDA
input01	Lung	L	ERBB2 MUT* (G776A)	only alteration type	YES	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	Responsive	434			C	cgi	ASCO 2017 (abstr 8510)
input01	Lung	L	ERBB2 MUT* (G776A)	only alteration type	YES	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	ERBB2 (V659E,S310F)	Responsive	435			C	cgi	ASCO 2017 (abstr 8510)
input01	Stomach	ST	ERBB2 MUT* (G776A)	only gene	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB2 amplification	Responsive	436			CASE REPORT	cgi	AACR 2014 (abstr CT228)
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB2 amplification	Responsive	437			B	cgi	PMID:20142587;PMID:22418700;PMID:23632474
input01	Bladder	BLCA	ERBB2 MUT* (G776A)	only gene	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB2 amplification	Responsive	438			CASE REPORT	cgi	PMID:27044931
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB2 proximal exon 20	Responsive	439			C	cgi	PMID:26598547;ASCO 2017 (abstr 9071)
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB2 (T798I)	Responsive	440			D	cgi	PMID:28274957
input01	Non-small cell lung	NSCLC	ERBB2 MUT* (G776A)	only alteration type	YES	Dacomitinib (Pan ERBB inhibitor)	ERBB2 oncogenic mutation	Responsive	441			C	cgi	PMID:25899785
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib (ERBB2 inhibitor);Capecitabine (Chemotherapy)	ERBB2 amplification	Responsive	442			A	cgi	FDA:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538
input01	Billiary tract	BT	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib (ERBB2 inhibitor)	ERBB2 amplification	Responsive	443			C	cgi	PMID:26022204
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib (ERBB2 inhibitor)	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	Responsive	444			D	cgi	PMID:23220880
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib (ERBB2 inhibitor);Capecitabine (Chemotherapy)	ERBB2 overexpression	Responsive	446			A	cgi	FDA:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s023lbl.pdf;PMID:17192538
input01	Breast adenocarcinoma, Lung adenocarcinoma	BRCA, LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib (ERBB2 inhibitor)	ERBB2 (V659E)	Responsive	447			CASE REPORT	cgi	PMID:23950206
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib (ERBB2 inhibitor)	ERBB2 proximal exon 20	Responsive	448			C	cgi	PMID:26598547;ASCO 2017 (abstr 9071)
input01	Stomach	ST	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy)	ERBB2 amplification	Responsive	449			C	cgi	PMID:25694417;NCT02015169
input01	Solid tumors	SOLID	ERBB2 MUT* (G776A)	only gene	YES	MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor)	ERBB2 overexpression	Responsive	450			C	cgi	ASCO 2013 (abstr 2605);PMID:26104654
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	Responsive	451			D	cgi	PMID:23220880
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 oncogenic mutation	Responsive	452			C	cgi	ESMO 2014 (abstr LBA39_PR)
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Neratinib (ERBB2 inhibitor)	ERBB2 amplification	Responsive	453			B	cgi	PMID:20142587;PMID:22418700;PMID:23632474
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 (K753E)	Responsive	454			D	cgi	PMID:27697991
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	Responsive	455			D	cgi	PMID:23220880
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 proximal exon 20	Responsive	456			C	cgi	PMID:26598547;ASCO 2017 (abstr 9071)
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 (L869R)	Responsive	457			CASE REPORT	cgi	PMID:28274957
input01	Any cancer type	CANCER	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 (S310,L755,V777)	Responsive	458			C	cgi	AACR 2017 (abstr CT001)
input01	Any cancer type	CANCER	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	Responsive	459			C	cgi	AACR 2017 (abstr CT001)
input01	Stomach	ST	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	462			C	cgi	PMID:24960402
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	463			A	cgi	FDA
input01	Billiary tract	BT	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	464			C	cgi	PMID:26022204
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab (ERBB2 mAb inhibitor)	ERBB2 overexpression	Responsive	465			A	cgi	FDA
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Tensirolimus (MTOR inhibitor)	ERBB2 oncogenic mutation	Responsive	466			C	cgi	ESMO 2014 (abstr LBA39_PR)
input01	Stomach, Gastroesophageal junction adenocarcinoma	ST, GEJA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	467			A	cgi	FDA
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	468			A	cgi	FDA
input01	Billiary tract	BT	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	469			C	cgi	PMID:26022204
input01	Head an neck	HNC	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	471			CASE REPORT	cgi	PMID:21380780
input01	Ovary	OV	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	472			C	cgi	PMID:20003286;PMID:12525520
input01	Breast adenocarcinoma, Any cancer type	BRCA, CANCER	ERBB2 MUT* (G776A)	only alteration type	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	Responsive	473			D	cgi	PMID:23220880;PMID:22908275
input01	Any cancer type	CANCER	ERBB2 MUT* (G776A)	only alteration type	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	Responsive	474			D	cgi	PMID:22908275
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 (G776L)	Responsive	475			CASE REPORT	cgi	PMID:16775247
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 overexpression	Responsive	476			A	cgi	FDA
input01	Stomach, Gastroesophageal junction adenocarcinoma	ST, GEJA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 overexpression	Responsive	477			A	cgi	FDA
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 proximal exon 20	Responsive	478			C	cgi	PMID:26598547;ASCO 2017 (abstr 9071)
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	ERBB2 amplification	Responsive	479			CASE REPORT	cgi	http://ascopubs.org/doi/full/10.1200/PO.16.00055
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)	ERBB2 amplification	Responsive	480			C	cgi	PMID:21107682;PMID:20975068
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor)	ERBB2 amplification	Responsive	481			C	cgi	PMID:21558407
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)	ERBB2 amplification	Responsive	482			B	cgi	ASCO 2015 (abstr 3508);NCT01104571;EBCC10
input01	Endometrium	ED	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)	ERBB2 amplification	Responsive	483			D	cgi	PMID:25294905
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A), ESR1 MUT (E380Q)	only gene	YES	Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc)	ERBB2 expression + ESR1 overexpression	Responsive	484			A	cgi	FDA
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A), ESR1 MUT (E380Q)	only gene	YES	Abemaciclib (CDK4/6 inhibitor)	ERBB2 expression + ESR1 overexpression	Responsive	485			C	cgi	PMID:26658964
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A), ESR1 MUT (E380Q)	only gene	YES	Everolimus (MTOR inhibitor)	ERBB2 expression + ESR1 overexpression	Responsive	486			A	cgi	FDA
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Palbociclib (CDK4/6 inhibitor)	ERBB2 expression -	Responsive	487			A	cgi	FDA: https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only alteration type	YES	ERBB3 mAb inhibitors	ERBB3 (P262H,G284R)	Responsive	489			D	cgi	PMID:23680147
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only alteration type	YES	PI3K pathway inhibitor + MEK inhibitors	ERBB3 (P262H,G284R,Q809R)	Responsive	490			D	cgi	PMID:23680147
input01	Bladder	BLCA	ERBB3 MUT (V104M)	only alteration type	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB3 (G284R,R103G)	Responsive	491			CASE REPORT	cgi	ASCO 2015 (abstr e15516)
input01	Bladder	BLCA	ERBB3 MUT (V104M)	complete	YES	Afatinib (ERBB2&EGFR inhibitor 2nd gen)	ERBB3 (G284R,V104M,R103G)	Responsive	492			CASE REPORT	cgi	PMID:27044931
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only alteration type	YES	Lapatinib (ERBB2 inhibitor)	ERBB3 (P262H,G284R,Q809R)	Responsive	493			D	cgi	PMID:23680147
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only alteration type	YES	Pertuzumab (ERBB2 mAb inhibitor)	ERBB3 (P262H,G284R)	Responsive	494			D	cgi	PMID:23680147
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only alteration type	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB3 (P262H,G284R,Q809R)	Responsive	495			D	cgi	PMID:23680147
input01	Liposarcoma	LIP	TP53 MUT (R249G)	complete	YES	MDM2 inhibitors	TP53 oncogenic mutation	Resistant	503			C	cgi	PMID:23084521;ASCO 2015 (abstr 10564)
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	complete	YES	novel ER degraders (GDC-0810,etc)	ESR1 (E380Q,537,538,L536,P535H)	Responsive	509			CASE REPORT	cgi	AACR 2015 (abstr CT231)
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	complete	YES	Fluvestrant (Hormonal therapy)	ESR1 oncogenic mutation	Responsive	511			B	cgi	PMID:27269946
input01	Breast adenocarcinoma	BRCA	TP53 MUT (R249G)	complete	YES	Abemaciclib (CDK4/CDK6 inhibitor)	TP53 oncogenic mutation	Resistant	521			C	cgi	PMID:27217383
input01	Lung squamous cell	LUSC	FGFR1 MUT (N577K)	only gene	YES	FGFR inhibitors	FGFR1 amplification	Responsive	527			CASE REPORT	cgi	PMID:27870574
input01	Endometrium	ED	FGFR1 MUT (N577K)	only gene	YES	FGFR inhibitors	FGFR1 amplification	Responsive	528			CASE REPORT	cgi	ASCO 2017 (abstr 2500)
input01	Lung squamous cell	LUSC	FGFR1 MUT (N577K)	only gene	YES	FGFR inhibitors	FGFR1 amplification	Responsive	529			C	cgi	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)
input01	Head an neck	HNC	FGFR1 MUT (N577K)	only gene	YES	FGFR inhibitors	FGFR1 amplification	Responsive	530			D	cgi	PMID:23418312
input01	Breast adenocarcinoma	BRCA	FGFR1 MUT (N577K)	only gene	YES	FGFR inhibitors (Lucitanib,etc)	FGFR1 amplification	Responsive	531			C	cgi	PMID:25193991
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	only gene	YES	Abiraterone (AR inhibitor)	AR amplification	Resistant	532			C	cgi	PMID:26537258
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	only alteration type	YES	Abiraterone (AR inhibitor)	AR (L702H,T878A)	Resistant	533			C	cgi	PMID:26537258
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Alectinib (ALK inhibitor)	ALK (I1171T)	Resistant	543			CASE REPORT	cgi	PMID:25228534
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	complete	YES	Arn-509 (AR inhibitor)	AR (F877L)	Resistant	549			CASE REPORT	cgi	PMID:23779130
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	FLT3 inhibitors	FLT3-ITD	Responsive	559			C	cgi	PMID:16857985
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	novel FLT3 inhibitors	FLT3 (F691)	Responsive	560			D	cgi	PMID:25847190
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Crenolanib (FLT3 inhibitor)	FLT3 (N676)	Responsive	561			D	cgi	PMID:24619500
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Lestaurtinib (Pan-TK inhibitor)	FLT3 (D835)	Responsive	562			CASE REPORT	cgi	PMID:16857985
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Midostaurin (Pan-TK inhibitor)	FLT3 (D835)	Responsive	563			CASE REPORT	cgi	PMID:20733134
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Midostaurin (Pan-TK inhibitor)	FLT3 (N676)	Responsive	564			D	cgi	PMID:24619500
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Quizartinib (Pan-TK inhibitor)	FLT3-ITD	Responsive	566	966	Resistant	C	cgi	ASH 2012 (abstr 673);ASH 2012 (abstr 48)
input01	Breast adenocarcinoma	BRCA	PTEN MUT* (K267X), PTEN MUT (R335*)	only alteration type	YES	BYL719 (PIK3CA inhibitor)	PTEN biallelic inactivation	Resistant	567			CASE REPORT	cgi	PMID:25409150
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	FLT3-ITD	Responsive	568	627	Resistant	C	cgi	PMID:19389879;PMID:22368270
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Sorafenib + Azacytidine (Pan-TK inhibitor + Chemotherapy)	FLT3-ITD	Responsive	569			C	cgi	PMID:23613521
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Ceritinib (ALK inhibitor)	ALK (G1123S)	Resistant	572			CASE REPORT	cgi	PMID:26134233
input01	Cutaneous melanoma	CM	GNAQ MUT* (Q209L)	complete	YES	HDAC inhibitors	GNAQ (Q209)	Responsive	583			D	cgi	NCT01587352
input01	Cutaneous melanoma	CM	GNAQ MUT* (Q209L)	complete	YES	PI3K pathway inhibitor + MEK inhibitors	GNAQ (Q209)	Responsive	584			D	cgi	PMID:22733540;PMID:22808163
input01	Cutaneous melanoma	CM	GNAQ MUT* (Q209L)	complete	YES	PKC inhibitors	GNAQ (Q209)	Responsive	585			D	cgi	PMID:22653968;PMID:22253748
input01	Cutaneous melanoma	CM	GNAQ MUT* (Q209L)	complete	YES	Selumetinib (MEK inhibitor)	GNAQ (Q209)	Responsive	586	427	Resistant	C	cgi	ASCO 2013 (abstr CRA9003)
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Cetuximab (EGFR mAb inhibitor)	BRAF (V600E)	Resistant	590			B	cgi	PMID:20619739;PMID:21163703;PMID:23325582
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	HSP90 inhibitors	KIT mutation in exon 11	Responsive	630			C	cgi	PMID:22898035
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	HSP90 inhibitors	KIT mutation in exon 9 or 17	Responsive	631			D	cgi	PMID:21737509
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	KIT wildtype	Responsive	632			D	cgi	PMID:16397263
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	KIT mutation in exon 9,11,13,14 or 17	Responsive	633			CASE REPORT	cgi	PMID:19671763
input01	Systemic mastocytosis	SM	KIT MUT (Y553N)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	KIT (D816V)	Responsive	634			C	cgi	PMID:18559612
input01	Acute myeloid leukemia	AML	KIT MUT (Y553N)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	KIT (D816V)	Responsive	635			CASE REPORT	cgi	PMID:18986703
input01	Any cancer type	CANCER	KIT MUT (Y553N)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	KIT (D816Y,D816F,D816V)	Responsive	636			D	cgi	PMID:16397263
input01	Acute myeloid leukemia	AML	KIT MUT (Y553N)	only alteration type	YES	Dasatinib (BCR-ABL inhibitor 2nd gen)	KIT (N822K)	Responsive	637			D	cgi	PMID:23149070
input01	Acute myeloid leukemia	AML	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT inframe deletion (416-422),inframe insertion (416-422)	Responsive	638			D	cgi	PMID:15618474
input01	Thymic	THYM	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT inframe deletion (V560)	Responsive	639			CASE REPORT	cgi	PMID:15201427
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT mutation in exon 9,11,13,14 or 17	Responsive	641			A	cgi	FDA
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT mutation in exon 9,11,13,14 or 17	Responsive	642			B	cgi	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT mutation in exon 9,11,13,14 or 17	Responsive	643			A	cgi	NCCN
input01	Colorectal adenocarcinoma	COREAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only alteration type	YES	Cetuximab (EGFR mAb inhibitor)	PTEN biallelic inactivation	Resistant	644			CASE REPORT	cgi	Caris molecular intelligence
input01	Female germ cell tumor, Male germ cell tumor	FGCT, MGCT	TP53 MUT (R249G)	complete	YES	Cisplatin (Chemotherapy)	TP53 oncogenic mutation	Resistant	647			C	cgi	PMID:27646943
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib (ALK inhibitor)	ALK inframe insertion (1151T)	Resistant	648			CASE REPORT	cgi	PMID:22277784
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT (D820Y)	Responsive	649			CASE REPORT	cgi	PMID:23775962
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	complete	YES	Crizotinib (ALK inhibitor)	ALK oncogenic mutation	Resistant	650			CLINICAL TRIALS	cgi	PMID:22235099
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib (ALK inhibitor)	ALK amplification	Resistant	651			CLINICAL TRIALS	cgi	PMID:22235099
input01	Thymic	THYM	KIT MUT (Y553N)	complete	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT (Y553N)	Responsive	652			CASE REPORT	cgi	PMID:21969494
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Nilotinib (BCR-ABL inhibitor 2nd gen)	KIT mutation in exon 9,11,13,14 or 17	Responsive	653			C	cgi	PMID:22068222;PMID:25695690
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Nilotinib (BCR-ABL inhibitor 2nd gen)	KIT mutation in exon 17	Responsive	654			C	cgi	PMID:22119758;PMID:21456006
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only alteration type	YES	Nilotinib (BCR-ABL inhibitor 2nd gen)	KIT (D820Y)	Responsive	655			CASE REPORT	cgi	PMID:25695690
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	KIT (788-828,829-860,550-592)	Responsive	656	956	Resistant	C	cgi	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	KIT (A829P,V654A,T670I)	Responsive	657	956	Resistant	D	cgi	PMID:25239608
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Regorafenib (Pan-kinase inhibitor)	KIT mutation in exon 9,11,13,14 or 17	Responsive	658			A	cgi	FDA
input01	Thymic	THYM	KIT MUT (Y553N)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	KIT inframe deletion (577-579)	Responsive	659	627	Resistant	CASE REPORT	cgi	PMID:20970876
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	KIT wildtype	Responsive	660	627	Resistant	C	cgi	ASCO 2011 (abstr 10009)
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Sorafenib (Pan-TK inhibitor)	KIT mutation in exon 9 or 11	Responsive	661	627	Resistant	C	cgi	PMID:22270258
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Sorafenib (Pan-TK inhibitor)	KIT (550-592,627-664,788-828,829-860)	Responsive	662	627	Resistant	CASE REPORT	cgi	PMID:18936790;PMID:20372153
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	KIT mutation in exon 17	Responsive	663	627	Resistant	D	cgi	PMID:23840364
input01	Thymic	THYM	KIT MUT (Y553N)	only alteration type	YES	Sorafenib (Pan-TK inhibitor)	KIT (D820E)	Responsive	664	627	Resistant	CASE REPORT	cgi	PMID:19461405
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Sunitinib (Pan-TK inhibitor)	KIT wildtype	Responsive	665	1023	Resistant	B	cgi	PMID:18955458
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Sunitinib (Pan-TK inhibitor)	KIT mutation in exon 9,11,13,14 or 17	Responsive	666	1023	Resistant	A	cgi	FDA
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib (ALK inhibitor)	ALK amplification	Resistant	667			CASE REPORT	cgi	PMID:22277784
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Sunitinib (Pan-TK inhibitor)	KIT mutation in exon 9,11,13,14 or 17	Responsive	668	1023	Resistant	B	cgi	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib (ALK inhibitor)	ALK (C1156Y,L1196M)	Resistant	669			CASE REPORT	cgi	PMID:20979473
input01	Glioma	G	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib (ALK inhibitor)	ALK (F1174L)	Resistant	670			D	cgi	PMID:22072639
input01	Thymic	THYM	KIT MUT (Y553N)	only alteration type	YES	Sunitinib (Pan-TK inhibitor)	KIT (H697Y)	Responsive	671	1023	Resistant	D	cgi	PMID:19861435
input01	Thymic	THYM	KIT MUT (Y553N)	only alteration type	YES	Sunitinib (Pan-TK inhibitor)	KIT (H697Y)	Responsive	672	1023	Resistant	D	cgi	PMID:19861435
input01	Thymic	THYM	KIT MUT (Y553N)	complete	YES	Sunitinib (Pan-TK inhibitor)	KIT (Y553N)	Responsive	673	1023	Resistant	CASE REPORT	cgi	PMID:23375402
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib (ALK inhibitor)	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	Resistant	678			CASE REPORT	cgi	PMID:22277784;PMID:25228534
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	complete	YES	Enzalutamide (AR inhibitor)	AR (F877L)	Resistant	707			CASE REPORT	cgi	PMID:23779130
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	complete	YES	Exemestane (Hormonal therapy)	ESR1 oncogenic mutation	Resistant	735			B	cgi	PMID:27269946
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	only alteration type	YES	Flutamide (AR inhibitor)	AR (T878A)	Resistant	736			CASE REPORT	cgi	PMID:2260966
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only alteration type	YES	Fulvestrant (Hormonal therapy)	ESR1 (Y537S)	Resistant	737			D	cgi	PMID:27986707
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT wildtype	Resistant	764			B	cgi	PMID:18955458
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT (627-664,664-714,449-514)	Resistant	765			B	cgi	PMID:18955458;PMID:18955451;PMID:16624552
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT mutation in exon 17	Resistant	768			D	cgi	PMID:23840364
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT mutation in exon 17 or 18	Resistant	769			C	cgi	PMID:21690468;PMID:21642685
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only gene	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT amplification	No Responsive	770			C	cgi	PMID:23775962
input01	Gastrointestinal stromal, Myelodisplasic syndrome, Myelodisplasic proliferative syndrome, Hyper eosinophilic advanced snydrome, Eosinophilic chronic leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Systemic mastocytosis	GIST, MDS, MDPS, HES, ECL, CML, ALL, SM	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT (D816)	Resistant	771			A	cgi	FDA
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT (T670I)	Resistant	772			A	cgi	PMID:24687822
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	Resistant	783			D	cgi	PMID:23582185;PMID:21689725;PMID:17259998
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib (ERBB2 inhibitor)	ERBB2 (K753E)	Resistant	819			D	cgi	PMID:27697991
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib (ERBB2 inhibitor)	ERBB2 (T798I)	Resistant	851			CASE REPORT	cgi	PMID:28274957
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only gene	YES	Osimertinib (3rd generation EGFR inhibitor)	ERBB2 amplification	Resistant	864			CASE REPORT	cgi	PMID:27252416
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Panitumumab (EGFR mAb inhibitor)	BRAF (V600E)	Resistant	889			B	cgi	PMID:20619739;PMID:21163703;PMID:23325582
input01	Colorectal adenocarcinoma	COREAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only alteration type	YES	Panitumumab (EGFR mAb inhibitor)	PTEN biallelic inactivation	Resistant	920			CASE REPORT	cgi	Caris molecular intelligence
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	FLT3 (D835,Y842)	Resistant	956			D	cgi	PMID:23430109
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only alteration type	YES	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	RET (I788N)	Resistant	964			D	cgi	PMID:28615362
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Quizartinib (Pan-TK inhibitor)	FLT3 (F691,D835,N676,Y842)	Resistant	966			D	cgi	PMID:22504184;PMID:23878140
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only gene	YES	Rociletinib (3rd generation EGFR inhibitor)	ERBB2 amplification	Resistant	978			CASE REPORT	cgi	PMID:27252416
input01	Pancreas	PA	PTEN MUT (R335*)	complete	YES	AKT inhibitors	PTEN oncogenic mutation	Responsive	1008			CASE REPORT	cgi	PMID:22025163
input01	Pancreas	PA	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	AKT inhibitors	PTEN deletion	Responsive	1009			CASE REPORT	cgi	PMID:22025163
input01	Breast adenocarcinoma	BRCA	PTEN MUT (R335*)	complete	YES	ATM inhibitors	PTEN oncogenic mutation	Responsive	1010			D	cgi	PMID:27397505
input01	Endometrium	ED	PTEN MUT (R335*)	complete	YES	PARP inhibitors	PTEN oncogenic mutation	Responsive	1011			CASE REPORT	cgi	PMID:21468130;PMID:20944090
input01	Endometrium	ED	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	PARP inhibitors	PTEN deletion	Responsive	1012			CASE REPORT	cgi	PMID:21468130;PMID:20944090
input01	Cutaneous melanoma	CM	PTEN MUT (R335*)	complete	YES	PD1 Ab inhibitors	PTEN oncogenic mutation	Responsive	1013			C	cgi	PMID:26645196
input01	Cutaneous melanoma	CM	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	PD1 Ab inhibitors	PTEN deletion	Responsive	1014			C	cgi	PMID:26645196
input01	Prostate adenocarcinoma	PRAD	PTEN MUT (R335*)	complete	YES	PI3K pathway inhibitor + AR antagonists	PTEN oncogenic mutation	Responsive	1015			D	cgi	PMID:21575859
input01	Prostate adenocarcinoma	PRAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	PI3K pathway inhibitor + AR antagonists	PTEN deletion	Responsive	1016			D	cgi	PMID:21575859
input01	Ovary	OV	PTEN MUT (R335*)	complete	YES	PI3K pathway inhibitor + MEK inhibitors	PTEN oncogenic mutation	Responsive	1017			D	cgi	PMID:21632463
input01	Ovary	OV	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	PI3K pathway inhibitor + MEK inhibitors	PTEN deletion	Responsive	1018			D	cgi	PMID:21632463
input01	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	TH, G, L, OV, BRCA, CANCER, ED	PTEN MUT (R335*)	complete	YES	PI3K pathway inhibitors	PTEN oncogenic mutation	Responsive	1019			D	cgi	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669
input01	Thyroid, Glioma, Lung, Ovary, Breast adenocarcinoma, Any cancer type, Endometrium	TH, G, L, OV, BRCA, CANCER, ED	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	PI3K pathway inhibitors	PTEN deletion	Responsive	1020			D	cgi	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669
input01	Prostate adenocarcinoma	PRAD	PTEN MUT (R335*)	complete	YES	PIK3CB inhibitors	PTEN oncogenic mutation	Responsive	1021			CASE REPORT	cgi	ASCO 2014 (abstr 2514)
input01	Prostate adenocarcinoma	PRAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	PIK3CB inhibitors	PTEN deletion	Responsive	1022			CASE REPORT	cgi	ASCO 2014 (abstr 2514)
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Sunitinib (Pan-TK inhibitor)	KIT mutation in exon 11	Resistant	1023			B	cgi	PMID:18955458
input01	Prostate adenocarcinoma	PRAD	PTEN MUT (R335*)	complete	YES	Everolimus (MTOR inhibitor)	PTEN oncogenic mutation	Responsive	1024			C	cgi	PMID:23582881
input01	Prostate adenocarcinoma	PRAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Everolimus (MTOR inhibitor)	PTEN deletion	Responsive	1025			C	cgi	PMID:23582881
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Sunitinib (Pan-TK inhibitor)	KIT mutation in exon 17	Resistant	1026			D	cgi	PMID:23840364
input01	Any cancer type	CANCER	PTEN MUT (R335*)	complete	YES	Sirolimus (MTOR inhibitor)	PTEN oncogenic mutation	Responsive	1027			C	cgi	ASCO 2013 (abstr 2532)
input01	Any cancer type	CANCER	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Sirolimus (MTOR inhibitor)	PTEN deletion	Responsive	1028			C	cgi	ASCO 2013 (abstr 2532)
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only gene	YES	Sunitinib (Pan-TK inhibitor)	KIT amplification	No Responsive	1029			C	cgi	PMID:22261812
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	complete	YES	Tamoxifen (Hormonal therapy)	ESR1 (E380Q,537,538,L536,P535H)	Resistant	1031			C	cgi	PMID:24185512;PMID:24185510;PMID:24398047
input01	Breast adenocarcinoma	BRCA	PTEN MUT (R335*), ERBB2 MUT* (G776A)	only gene	YES	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)	PTEN oncogenic mutation + ERBB2 amplification	Responsive	1033			B	cgi	PMID:27091708
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	RET inhibitors	RET fusion	Responsive	1052			D	cgi	PMID:22327624;PMID:22327622
input01	Thyroid	TH	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	RET inhibitors	RET-TPCN1 fusion	Responsive	1053			D	cgi	PMID:23056499
input01	Thyroid	TH	RET MUT (M918T)	complete	YES	RET inhibitors	RET (C634W,M918T)	Responsive	1054			D	cgi	PMID:23056499
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Cabozantinib (Pan-kinase inhibitor)	RET fusion	Responsive	1055			C	cgi	PMID:28447912
input01	Thyroid carcinoma	THCA	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Cabozantinib (Pan-kinase inhibitor)	RET-TPCN1 fusion	Responsive	1056			D	cgi	PMID:21470995
input01	Thyroid	TH	RET MUT (M918T)	complete	YES	Cabozantinib (Pan-kinase inhibitor)	RET (C634W,M918T)	Responsive	1057			D	cgi	PMID:21470995
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Nintedanib (Pan-TK inhibitor)	RET fusion	Responsive	1058			CASE REPORT	cgi	PMID:26787234
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Sunitinib (Pan-TK inhibitor)	RET fusion	Responsive	1060	1023	Resistant	C	cgi	PMID:28447912
input01	Thyroid carcinoma	THCA	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Sunitinib (Pan-TK inhibitor)	RET-TPCN1 fusion	Responsive	1061	1023	Resistant	D	cgi	PMID:21470995
input01	Thyroid	TH	RET MUT (M918T)	complete	YES	Sunitinib (Pan-TK inhibitor)	RET (C634W,M918T)	Responsive	1062	1023	Resistant	D	cgi	PMID:21470995
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Vandetanib (Pan-TK inhibitor)	RET fusion	Responsive	1063			C	cgi	PMID:28447912
input01	Thyroid carcinoma	THCA	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Vandetanib (Pan-TK inhibitor)	RET-TPCN1 fusion	Responsive	1064			D	cgi	PMID:21470995
input01	Thyroid carcinoma	THCA	RET MUT (M918T)	complete	YES	Vandetanib (Pan-TK inhibitor)	RET (618,620,634,768,791,891,918,C634W,M918T)	Responsive	1065			A	cgi	PMID:20065189;PMID:22025146
input01	Endometrium	ED	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab (ERBB2 mAb inhibitor)	ERBB2 amplification	No Responsive	1075			C	cgi	PMID:26099744;PMID:19840887
input01	Any cancer type	CANCER	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF inframe deletion (L485),inframe deletion (P490)	Resistant	1098			D	cgi	PMID:26732095
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib (BRAF inhibitor)	BRAF (V600)	No Responsive	1108			C	cgi	PMID:26287849
input01	Acute myeloid leukemia	AML	TP53 MUT (R249G)	only alteration type	YES	HDM2 inhibitors	TP53 wildtype	Responsive	1118			C	cgi	AACR 2017 (abstr CT152)
input01	Any cancer type	CANCER	TP53 MUT (R249G)	only alteration type	YES	HSP90 inhibitors	TP53 (R248Q,R175H)	Responsive	1119			D	cgi	PMID:26009011
input01	Any cancer type	CANCER	TP53 MUT (R249G)	only alteration type	YES	HSP90 inhibitors	TP53 (R248Q,R175H)	Responsive	1120			D	cgi	PMID:26009011
input01	Head an neck	HNC	TP53 MUT (R249G)	complete	YES	WEE1 inhibitors	TP53 oncogenic mutation	Responsive	1122			D	cgi	PMID:25125259
input01	B cell lymphoma	BCL	TP53 MUT (R249G)	complete	YES	AZD6738 (ATR inhibitor)	TP53 oncogenic mutation	Responsive	1124			C	cgi	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html
input01	B cell lymphoma	BCL	TP53 MUT (R249G)	only gene	YES	AZD6738 (ATR inhibitor)	TP53 deletion	Responsive	1125			C	cgi	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html
input01	Acute myeloid leukemia, Myelodisplasic proliferative syndrome	AML, MDPS	TP53 MUT (R249G)	complete	YES	Decitabine (Chemotherapy)	TP53 oncogenic mutation	Responsive	1127			C	cgi	PMID:27959731
input01	Bladder	BLCA	TP53 MUT (R249G)	complete	YES	Doxorubicin (Anthracycline antitumor antibiotic)	TP53 oncogenic mutation	Responsive	1128			D	cgi	PMID:27397505
input01	Bladder	BLCA	TP53 MUT (R249G)	complete	YES	Gemcitabine (Chemotherapy)	TP53 oncogenic mutation	Responsive	1129			D	cgi	PMID:27397505
input01	Bladder	BLCA	TP53 MUT (R249G)	complete	YES	Mitomycin C (Chemotherapy)	TP53 oncogenic mutation	Responsive	1130			D	cgi	PMID:27397505
input01	Ovary	OV	TP53 MUT (R249G)	complete	YES	WEE1 inhibitors	TP53 oncogenic mutation	Responsive	1131			C	cgi	PMID:27998224
input01	Thymic	THYM	TP53 MUT (R249G)	complete	YES	Pramlintide (Amylin analogue)	TP53 oncogenic mutation	Responsive	1132			D	cgi	PMID:25409149
input01	Thymic	THYM	TP53 MUT (R249G)	only gene	YES	Pramlintide (Amylin analogue)	TP53 deletion	Responsive	1133			D	cgi	PMID:25409149
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Venetoclax (BCL2 inhibitor)	FLT3-ITD	Resistant	1145			C	cgi	PMID:27520294
input01	Renal angiomyolipoma    	RA	TSC2 MUT (Q1178*)	complete	YES	MTOR inhibitors	TSC2 oncogenic mutation	Responsive	1153			C	cgi	PMID:23312829;PMID:21525172;PMID:20048174
input01	Lymphangioleiomyomatosis	LAM	TSC2 MUT (Q1178*)	complete	YES	SRC inhibitors	TSC2 oncogenic mutation	Responsive	1154			D	cgi	PMID:24691995
input01	Lymphangioleiomyomatosis	LAM	TSC2 MUT (Q1178*)	only gene	YES	SRC inhibitors	TSC2 deletion	Responsive	1155			D	cgi	PMID:24691995
input01	Bladder	BLCA	TSC2 MUT (Q1178*)	complete	YES	Everolimus (MTOR inhibitor)	TSC2 oncogenic mutation	Responsive	1156			C	cgi	PMID:22923433
input01	Renal angiomyolipoma    , Giant cell astrocytoma	RA, GCA	TSC2 MUT (Q1178*)	complete	YES	Everolimus (MTOR inhibitor)	TSC2 oncogenic mutation	Responsive	1157			A	cgi	FDA
input01	Thyroid carcinoma	THCA	TSC2 MUT (Q1178*)	complete	YES	Everolimus (MTOR inhibitor)	TSC2 (Q1178*)	Responsive	1158			CASE REPORT	cgi	PMID:25295501
input01	Endometrium	ED	TSC2 MUT (Q1178*)	only alteration type	YES	Tensirolimus (MTOR inhibitor)	TSC2 (E66K)	Responsive	1159			CASE REPORT	cgi	PMID:27016228
input01	Any cancer type	CANCER	PTEN MUT (R335*)	complete	YES	Gsk2636771 + Azd8186	PTEN (D326N,G165R,T277A,T160I,G129E,G165V,N48K,H93Y,N94I,D92E,D92G,F21A,R173P,L112R,K289E,L108P,R335L,H123Y,R130G,D92V,G251C,R15S,L181P,V133I,C124R,T131A,.,V343L,A126V,T131L,L112P,R173C,G129A,H61D,C136R,H123Q,H61R,P96Q,D331G,M134L,N276S,K342N,Y68H,D92N,M35R,Y68D,P95S,R130Q,R173H,Y155C,H123D,G20E,K62R,R159G,S10N,L23F,C105F,D162G,T319A,Y16C,A126D,H93R,K128Q,I122S,Y65C,F154L,K128T,R130K,R130L,V343E,G36R,A126S,D252G,G127N,F347L,G127E,K125E,A39P,S170N,G165E,P169H,Y27S,V217D,D162H,H118P,D92A,A34D,D24Y,L345Q,T131I,D92H,K128N,T167A,S170R,T401I,P95L,C124S,P38L,S227F,C124N,A121P,G129D,K128R,C136Y,F341V,K125L,R130A,D24N,H93D,L325F,C71Y,E157G,L42R,Y174N,A121E,A126G,G129R,R161G,G44D,I168F,R15K,H93Q,I122L,F241S,D107Y,K125M,L320S)	Responsive	1			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/PTEN
input01	Any cancer type	CANCER	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Gsk2636771 + Azd8186	PTEN deletion	Responsive	2			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/PTEN
input01	Lung squamous cell	LUSC	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1 amplification	Responsive	7			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Sarcoma	S	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib + Ceritinib	ALK fusion	Responsive	19			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ALK
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Alectinib	ALK (G1202R,I1171N)	Resistant	20			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ALK
input01	Any cancer type	CANCER	BRAF MUT (G469A)	complete	YES	Plx8394	BRAF (D594.,G466.,G464.,N581.,D287H,K601.,G469.,G596.,L597.,F595L,S467L,V459L)	Responsive	25			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/BRAF
input01	Thymic	THYM	KIT MUT (Y553N)	complete	YES	Sunitinib + Sorafenib	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,D816.,N655K,K642E,V560D,W557C,D60N,D816H)	Responsive	26			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/KIT
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib	KIT (Y823D,T670I,V654A,D820G,C809G,D820A,N822K,D816H)	Resistant	27			C	CIVIC,oncokb	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,L755W,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Responsive	29			C	CIVIC,oncokb	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Neratinib	ERBB2 amplification	Responsive	30			B	CIVIC,oncokb	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ERBB2|CIVIC=https://civicdb.org/genes/20/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Panitumumab + Dabrafenib + Trametinib	BRAF (V600)	Responsive	45			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/BRAF
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Encorafenib + Binimetinib + Cetuximab	BRAF (V600E)	Responsive	46			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/BRAF
input01	Ovary	OV	BRAF MUT (G469A)	only gene	YES	Cobimetinib + Trametinib	BRAF fusion	Responsive	47			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/BRAF
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	complete	YES	Azd9496 + Fulvestrant	ESR1 (L536P,S463P,L469V,L536Q,Y537N,.,L536H,Y537C,Y537S,D538G,L536R,E380Q)	Responsive	48			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Azd9496 + Fulvestrant	ESR1-CCDC170 fusion	Responsive	49			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Azd9496 + Fulvestrant	ESR1-DAB2 fusion	Responsive	50			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Azd9496 + Fulvestrant	ESR1-GYG1 fusion	Responsive	51			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Azd9496 + Fulvestrant	ESR1-SOX9 fusion	Responsive	52			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Azd9496 + Fulvestrant	ESR1-YAP1 fusion	Responsive	53			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Azd9496 + Fulvestrant	ESR1 fusion	Responsive	54			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ESR1
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	complete	YES	Imatinib	KIT (F522C,W557R,N463S,V654A,N822H,A829P,D820A,D572A,P838L,R634W,N822K,Y578C,N822Y,D816G,D816A,T670I,D820G,V560E,K558N,C809G,D820E,D820Y,D816Y,L576P,N822I,W557G,H697Y,I653T,V559A,V530I,V559I,S476I,V559G,D52N,.,N505I,S709F,V559C,D816N,D816V,M541L,V559D,Y823D,C443Y,D816E,Y553N,V560G,V852I,D816F,Y570H,K509I,E490K,N655K,V560D,K642E,D816.,W557C,D60N,D816H)	Responsive	55			B	CIVIC,oncokb	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/KIT|CIVIC=https://civicdb.org/genes/29/summary
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only gene	YES	Imatinib	KIT amplification	Responsive	56			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/KIT
input01	Mastocytosis	MAS	KIT MUT (Y553N)	only alteration type	YES	Blu-285	KIT (D816)	Responsive	57			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/KIT
input01	Renal clear cell	RCCC	TSC2 MUT (Q1178*)	complete	YES	Everolimus	TSC2 (S1653P,Q1503P,R905G,L830R,A889P,L146R,T1203K,V1673F,W1610G,V769E,C696Y,F615S,E75G,L448P,V299G,R611W,R1200W,R505Q,Q1554H,G1567D,G1596V,Y1571N,I427M,S1498N,L1584R,P1709L,L844R,V705E,R905Q,Y598C,L410R,R462C,R611Q,R905W,A614D,.,S1653F,P1675L,H1620R,S1036P,H597Y,L493P,T1623I,V1673D,V705M,L826P,L792R,A328P,L493V)	Responsive	73			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/TSC2
input01	Renal clear cell	RCCC	TSC2 MUT (Q1178*)	only gene	YES	Everolimus	TSC2 deletion	Responsive	74			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/TSC2
input01	Non-small cell lung	NSCLC	ERBB2 MUT* (G776A)	only alteration type	YES	Ado + Trastuzumab + Neratinib	ERBB2 (T862A,L755S,V842I,V777A,D769H,.,R896C,R678W,R784C,V773A,C630Y,G309E,G292R,E645F,T733I,D769Y,G660R,T686A,D769A,Y803N,L651V,A644F,L674V,V839G,R217C,L869R,E719K,G660D,E265K,L785F,P650S,D277H,D808N,G776V,S653C,R487W,L841V,S310F,E693K,S335C,V659E,V794M,V659K,E321G,L915M,L866M,C311R,S1002R,D277Y,V659G,Q709L,L726I,G309A,N857S,L755P,T798M,L663P,E812K,S656C,T798I,R683Q,I682G,R678Q,V777L,P780L,A710V,R677L,S310Y,S783P,E717K,E719G,H878Y,G776S,L726F,D821N,V777M,I767M,S649T,C334S)	Responsive	75			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2
input01	Non-small cell lung	NSCLC	ERBB2 MUT* (G776A)	only gene	YES	Ado + Trastuzumab + Neratinib	ERBB2 amplification	Responsive	76			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ERBB2
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Trametinib	BRAF (V600K,V600.,L597.,K601.,V600E,L597V)	Responsive	98			B	CIVIC,oncokb	CIVIC,oncokb: CIVIC=https://civicdb.org/genes/5/summary|oncokb=https://www.oncokb.org/gene/BRAF
input01	Histiocytoma	HIS	ARAF MUT (S217F)	complete	YES	Sorafenib	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Responsive	101	627	Resistant	C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/ARAF
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1 amplification	Responsive	102			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-BCR fusion	Responsive	103			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-CEP110 fusion	Responsive	104			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-CUX1 fusion	Responsive	105			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-ERLIN2 fusion	Responsive	106			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-TACC1 fusion	Responsive	107			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-FGFR1OP1 fusion	Responsive	108			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1 fusion	Responsive	109			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	complete	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1 (V592M,K687E,.,N577K)	Responsive	110			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Any cancer type	CANCER	FGFR1 MUT (N577K)	only gene	YES	Azd4547 + Nvp-Bgj398 + Erdafitinib + 1265229-25-1	FGFR1-ZNF198 fusion	Responsive	111			D	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/FGFR1
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (C1156Y,F1174L,L1196M,G1269A)	Resistant	119			D	CIVIC,oncokb	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ALK|CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Cabozantinib + Vandetanib + Larotrectinib + 292 + 667	RET fusion	Responsive	123			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/RET
input01	Thyroid medullary	THM	RET MUT (M918T)	complete	YES	Larotrectinib + 292 + 667	RET (C618R,C620R,C609Y,E768D,C630R,S904F,E511K,C634S,C634Y,V648I,I852M,S891A,A883T,A883F,C611Y,T338I,C634W,K603Q,D631Y,M918T,A919V,R833C,.,V804M,C634R,V804L,Y806C,M918V,L790F,M848T,R886W,Y791F)	Responsive	124			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/RET
input01	Thyroid medullary	THM	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Larotrectinib + 292 + 667	RET fusion	Responsive	125			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/RET
input01	Thyroid medullary	THM	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Larotrectinib + 292 + 667	RET-KIF5B fusion	Responsive	126			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/RET
input01	Thyroid medullary	THM	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Larotrectinib + 292 + 667	RET-CCDC6 fusion	Responsive	127			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/RET
input01	Thymic	THYM	KIT MUT (Y553N)	only gene	YES	Sunitinib + Sorafenib	KIT amplification	Responsive	128			B	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/KIT
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Cobimetinib + Trametinib	BRAF fusion	Responsive	131			C	oncokb	oncokb: oncokb=https://www.oncokb.org/gene/BRAF
input01	Non-small cell lung	NSCLC	ARAF MUT (S217F)	complete	YES	Sorafenib	ARAF (G322S,S214T,F351L,.,S214C,N217I,S214A,S214F)	Responsive	140	627	Resistant	C	CIVIC,oncokb	CIVIC,oncokb: oncokb=https://www.oncokb.org/gene/ARAF|CIVIC=https://civicdb.org/genes/3/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C)	complete	YES	Crizotinib	ALK (F1245C,F1174L)	Resistant	165			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C)	complete	YES	Lorlatinib	ALK (F1245C,F1174L,R1275Q)	Responsive	166			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Ipi + 504 + Crizotinib	ALK (EML4-ALK)	Responsive	167			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK (EML4-ALK)	Responsive	168	165	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Anaplastic large cell lymphoma	ALCL	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (HIP1-ALK I1171N)	Resistant	169			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Any cancer type	CANCER	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK (NPM-ALK)	Responsive	170	165	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (L1196M;ALK__EML4,S1206Y;ALK__EML4,V1180L;ALK__EML4,C1156Y;ALK__EML4,G1269A;ALK__EML4,L1152R;ALK__EML4)	Resistant	171			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (F1174L,R1275Q)	Responsive	172	165	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Tae684	ALK (R1275Q)	Resistant	173			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (V1180L)	complete	YES	Ceritinib	ALK (V1180L;ALK__EML4,S1206Y;ALK__EML4,L1196M;ALK__EML4)	Responsive	174			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Alectinib	ALK (EML4-ALK L1196M)	Responsive	175	399	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	176	165	Resistant	A	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Colorectal adenocarcinoma	COREAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	177	165	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Alectinib	ALK fusion	Responsive	178	399	Resistant	A	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Difuse large B Cell lymphoma	DLBCL	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Tae684	ALK (CLTC-ALK)	Responsive	179			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Any cancer type	CANCER	BRAF MUT (G469A)	complete	YES	Vemurafenib	BRAF (G464V,N581S,G596R,G469A,G466V,P731T,G496A,G606E)	Responsive	199	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Trametinib + Vemurafenib	BRAF (L597R,L597S,L597Q,K601E)	Responsive	200			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600K,V600D,L597R,V600E)	Responsive	201	203	Resistant	A	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Cobimetinib + Vemurafenib	BRAF (V600K)	Responsive	202			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	complete	YES	Vemurafenib	BRAF (G469A,V600E,L505H)	Resistant	203			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib	BRAF (V600E)	Resistant	204			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	complete	YES	Cetuximab	BRAF (.,G469A,V600E,D594G)	Resistant	205			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Thyroid carcinoma	THCA	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	206	203	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Leukemia	LK	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	207	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colon carcinoma	COC	BRAF MUT (G469A)	only alteration type	YES	Regorafenib	BRAF (V600E)	Responsive	208			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Glioma	G	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	209	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Lung adenocarcinoma	LUAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	210	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Histiocytoma	HIS	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	211	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Cetuximab + Panitumumab	BRAF (V600E,D594G)	Resistant	212			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Selumetinib + Nvp + Dactolisib	BRAF (V600E)	Responsive	213			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Panitumumab + Cetuximab	BRAF (V600E)	Resistant	214			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Fluorouracil	BRAF (V600E)	Resistant	215			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Bevacizumab	BRAF (V600E)	Resistant	216			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib	BRAF (V600K,V600.,V600E,K601E,V600D)	Responsive	217			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Thyroid carcinoma	THCA	BRAF MUT (G469A)	only alteration type	YES	Ci 1040	BRAF (V600E)	Responsive	218			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Thyroid carcinoma	THCA	BRAF MUT (G469A)	only alteration type	YES	Rdea 119	BRAF (V600E)	Responsive	219			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Thyroid carcinoma	THCA	BRAF MUT (G469A)	only alteration type	YES	Sorafenib	BRAF (V600E)	Responsive	220	627	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	2-Butanone + Sorafenib	BRAF (D594A,K483M)	Responsive	221			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Any cancer type	CANCER	BRAF MUT (G469A)	only gene	YES	Vemurafenib	BRAF-MACF1 fusion	Responsive	222	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600.,V600E)	Responsive	223	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600.,G596R)	Resistant	224			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only alteration type	YES	Cetuximab	ERBB2 (V777L,V842I,L755S,L866M)	Resistant	250			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib	ERBB2 (L755S)	Resistant	251			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Head an neck squamous	HNSC	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib	ERBB2 overexpression	Responsive	252			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colon carcinoma	COC	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib + Neratinib + Trastuzumab	ERBB2 (V777L,L755S)	Responsive	253			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Non-small cell lung	NSCLC	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab	ERBB2 amplification	Responsive	254			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Afatinib	ERBB2 amplification	Responsive	255			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Stomach	ST	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib	ERBB2 amplification	Responsive	256			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab	ERBB2 amplification	Responsive	257			A	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pp242	ERBB2 amplification	Responsive	258			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Lapatinib	ERBB2 amplification	Responsive	259			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only alteration type	YES	Fulvestrant + Tamoxifen	ESR1 (L536Q,Y537N,Y537C,Y537S,D538G)	Responsive	260			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/21/summary
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only alteration type	YES	Hormones	ESR1 (L536Q,Y537N,Y537C,Y537S,D538G)	Resistant	261			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/21/summary
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only alteration type	YES	Palbociclib	ESR1 (S463P,Y537N,Y537C,Y537S,D538G)	Responsive	262			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/21/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Sunitinib	FLT3 (D835V,D835.,D835H)	Responsive	268			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Tandutinib	FLT3 (D835V)	Resistant	269			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Renal clear cell	RCCC	FLT3 MUT* (D835-)	only alteration type	YES	Sunitinib	FLT3 (T227M)	Increased_Toxicity	270			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Ponatinib + Quizartinib	FLT3 (D835)	Resistant	271			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Sunitinib	KIT (V654A,K642E,D816H)	Responsive	278			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only alteration type	YES	Dasatinib	KIT (V559D,K642E,L576P)	Responsive	279			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Any cancer type	CANCER	KIT MUT (Y553N)	only alteration type	YES	Sunitinib + Tandutinib + Bis(2-Mercaptoethylsulfone) + Imatinib	KIT (V559D)	Responsive	280			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib + Sorafenib + Nilotinib + Dasatinib	KIT (V559D)	Responsive	281			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Regorafenib	KIT (K642E,V560G,L576P,N822K,V559D)	Responsive	282			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Regorafenib	KIT (T670I,V654A,D820G,D820A,N822K,D816H)	Resistant	283			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Sunitinib	KIT (N822K,V560G,L576P,D816V,V559D)	Resistant	284			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Acute myeloid leukemia	AML	KIT MUT (Y553N)	only alteration type	YES	Dasatinib	KIT (D816V)	Responsive	285			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Endometrial adenocarcinoma	EDA	PTEN MUT (R335*)	complete	YES	Everolimus	PTEN oncogenic mutation	Responsive	327			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Alectinib	RET fusion	Responsive	328	399	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Cabozantinib	RET fusion	Responsive	329			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Breast adenocarcinoma	BRCA	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Vandetanib	RET expression	Responsive	330			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Gastrointestinal stromal	GIST	RET MUT* (DVYE898-901-), RET MUT (M918T)	only alteration type	YES	Regorafenib	RET (C634W)	Responsive	331			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Any cancer type	CANCER	TP53 MUT (R249G)	only alteration type	YES	Amgmds3	TP53 (M237I,R248Q,R249S,V157F,R280T,R158H,R280K,R158L,G245S)	Resistant	333			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Stomach	ST	TP53 MUT (R249G)	complete	YES	2-Aminoethyl Dihydrogen Phosphate	TP53 (R213P,Y220C,R282L,R273C,.,R175H)	Responsive	334			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Non-small cell lung	NSCLC	TP53 MUT (R249G)	complete	YES	Docetaxel + Selumetinib	TP53 oncogenic mutation	Responsive	335			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Colorectal adenocarcinoma	COREAD	APC MUT* (KIGT1310-1313X)	only alteration type	YES	G007	APC oncogenic mutation	Responsive	344			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/66/summary
input01	Breast adenocarcinoma	BRCA	AR MUT (F877L)	only gene	YES	Nvp + Dactolisib	AR overexpression	Responsive	345			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/67/summary
input01	Non-small cell lung	NSCLC	ERBB3 MUT (V104M)	only alteration type	YES	Pertuzumab + Afatinib	ERBB3 (V855A)	Responsive	354			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only gene	YES	Selumetinib + Cp-724714 + Gefitinib	ERBB3 overexpression	Resistant	355			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Ewing sarcoma	EWS	FGFR1 MUT (N577K)	only gene	YES	Ponatinib	FGFR1 amplification	Responsive	358			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Breast adenocarcinoma	BRCA	FGFR1 MUT (N577K)	only gene	YES	Azd4547	FGFR1 amplification	Responsive	359			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Breast adenocarcinoma	BRCA	FGFR1 MUT (N577K)	only gene	YES	Dovitinib	FGFR1 amplification	Responsive	360			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Cutaneous melanoma	CM	GNAQ MUT* (Q209L)	only alteration type	YES	Plx-4720	GNAQ (Q209P)	Resistant	365			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
input01	Lung	L	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (F1174L)	Resistant	393			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Azd3463	ALK (F1174L)	Responsive	394			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	P154	ALK (EML4-ALK)	Responsive	395			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (G1269A;ALK__EML4,I1171N;ALK__HIP1,C1156Y;ALK__EML4,L1196M;ALK__EML4)	Resistant	396			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Alectinib + Crizotinib	ALK (I1171N;ALK__HIP1,I1171S;ALK__EML4)	Resistant	397			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Lung	L	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (G1269A;ALK__EML4,I1171S;ALK__EML4)	Resistant	398			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (V1180L)	complete	YES	Alectinib	ALK (EML4-ALK V1180L)	Resistant	399			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Any cancer type	CANCER	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Entrectinib	ALK fusion	Responsive	400			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Difuse large B Cell lymphoma	DLBCL	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK (CLTC-ALK)	Responsive	401	165	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ARAF MUT (S217F)	only alteration type	YES	Trametinib	ARAF (S214C)	Responsive	403			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/3/summary
input01	Any cancer type	CANCER	KIT MUT (Y553N)	only alteration type	YES	Dasatinib	KIT (V559D)	Responsive	409			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Chronic myeloid leukemia	CML	KIT MUT (Y553N)	only alteration type	YES	Dasatinib	KIT (V654A,D816V,V560G,D816H)	Responsive	410			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Chronic myeloid leukemia	CML	KIT MUT (Y553N)	only alteration type	YES	Bosutinib Monohydrate	KIT (D816V)	Resistant	411			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Any cancer type	CANCER	CSF1R MUT (Y969*)	only gene	YES	2580 + Imatinib	CSF1R (MEF2D-CSF1R)	Responsive	418			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/33/summary
input01	Head an neck squamous	HNSC	PTEN MUT (R335*)	complete	YES	Taselisib + Gdc	PTEN oncogenic mutation	Resistant	444			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Vandetanib	RET fusion	Responsive	445			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Thyroid medullary	THM	RET MUT (M918T)	complete	YES	Sorafenib	RET (M918T)	Responsive	446	627	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Thyroid medullary	THM	RET MUT (M918T)	complete	YES	Azd1480	RET (M918T)	Responsive	447			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Chronic lymphocytic leukemia	CLL	TP53 MUT (R249G)	complete	YES	Alemtuzumab	TP53 oncogenic mutation	Responsive	449			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Trametinib	BRAF (KIAA1549-BRAF)	Responsive	455			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	complete	YES	Panitumumab + Cetuximab	BRAF oncogenic mutation	Responsive	456			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Any cancer type	CANCER	BRAF MUT (G469A)	complete	YES	Trametinib	BRAF oncogenic mutation	Responsive	457			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Pancreas adenocarcinoma	PAAD	BRAF MUT (G469A)	only gene	YES	Vemurafenib	BRAF (CUX1-BRAF)	Responsive	458	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Vemurafenib	BRAF (TRIM24-BRAF)	Resistant	459			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Ro4987655	BRAF (,V600.)	Responsive	460			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Plx-4720 + Nutlin-3	BRAF (V600E)	Responsive	461			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	462	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Trametinib + 391210-10-9	BRAF (V600E)	Resistant	463			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Pictilisib	BRAF (V600E)	Responsive	464			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Uveal melanoma	UVM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	465	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Thyroid papillary	THP	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	466	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Multiple myeloma	MM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	467	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Oxaliplatin	BRAF (D594K,V600E)	Resistant	468			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Irinotecan	BRAF (D594K,V600E)	Resistant	469			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Pd 0325901	BRAF (V600E)	Responsive	470			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Pd 0325901	BRAF (V600E)	Responsive	471			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Trametinib + Sorafenib	BRAF (D594V)	Responsive	472			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Trametinib	BRAF (ZKSCAN1-BRAF)	Responsive	473			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Panitumumab	BRAF (V600)	Resistant	474			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib + Neratinib	ERBB2 (R678Q)	Responsive	491			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colon carcinoma	COC	ERBB2 MUT* (G776A)	only alteration type	YES	Neratinib + Lapatinib + Trastuzumab	ERBB2 (L866M)	Responsive	492			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pertuzumab + Trastuzumab + Docetaxel	ERBB2 amplification	Responsive	493			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Lapatinib	ERBB2 amplification	Responsive	494			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Pilaralisib	ERBB2 amplification	Responsive	495			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Stomach	ST	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab	ERBB2 amplification	Responsive	496			A	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Pictilisib	ERBB2 amplification	Responsive	497			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only alteration type	YES	Aromatase	ESR1 (S463P)	Resistant	498			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/21/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Jq-1	FLT3 (D835V)	Responsive	501			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Mucosal melanoma	MUCM	KIT MUT (Y553N)	only gene	YES	Imatinib	KIT amplification	Resistant	504			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Acute myeloid leukemia	AML	KIT MUT (Y553N)	only alteration type	YES	Imatinib Mesylate	KIT (N822K)	Responsive	505			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only alteration type	YES	Sorafenib + Nilotinib + Imatinib	KIT (L576P)	Resistant	506			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Colon carcinoma	COC	APC MUT* (KIGT1310-1313X)	only alteration type	YES	Jw 55	APC oncogenic mutation	Responsive	519			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/66/summary
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	complete	YES	Nilutamide + Cyproterone + Flutamide + Bicalutamide	AR oncogenic mutation	Resistant	520			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/67/summary
input01	Bladder	BLCA	ERBB3 MUT (V104M)	complete	YES	Afatinib	ERBB3 (V104M,G284R,R103G)	Responsive	526			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Stomach	ST	FGFR1 MUT (N577K)	only gene	YES	Nvp-Bgj398	FGFR1 expression	Responsive	528			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Ewing sarcoma	EWS	FGFR1 MUT (N577K)	only alteration type	YES	Ponatinib	FGFR1 (N546K)	Responsive	529			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Non-small cell lung	NSCLC	FGFR1 MUT (N577K)	only gene	YES	219580-11-7	FGFR1 amplification	Responsive	530			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Non-small cell lung	NSCLC	FGFR1 MUT (N577K)	only gene	YES	Dovitinib	FGFR1 amplification	Responsive	531			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Uveal melanoma	UVM	GNAQ MUT* (Q209L)	complete	YES	N-(1-Benzyl-2 + 3-Dihydroxy-4-{3-Methyl-2-[2-(2-Methyl-Propane-2-Sulfonylmethyl)-3-Naphthalen-1-Yl-Propionylamino]-Butyrylamino}-5-Phenyl-Pentyl)-3-Methyl-2-[2-(2-Methyl-Propane-2-Sulfonylmethyl)-3-Naphthalen-1-Yl-Propionylamino]-Butyramide	GNAQ (Q209)	Responsive	536			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
input01	Non-small cell lung	NSCLC	MAPK1 MUT (E322K)	only gene	YES	Wz4002	MAPK1 amplification	Resistant	555			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/4532/summary
input01	Head an neck squamous	HNSC	MAPK1 MUT (E322K)	complete	YES	Erlotinib	MAPK1 (E322K)	Responsive	556	827	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/4532/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only gene	YES	Dabrafenib + Panitumumab	BRAF amplification	Resistant	565			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Trametinib	BRAF (TRIM24-BRAF)	Responsive	566			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Thyroid papillary	THP	BRAF MUT (G469A)	only alteration type	YES	Dasatinib	BRAF (V600E)	Responsive	567			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Sarcoma	S	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	568	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Malignant astrocytoma	MA	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	569	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Ovary	OV	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	570	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Malignant peripheral nerve sheat tumor	MPN	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	571	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib + Gefitinib + Cetuximab	BRAF (V600E)	Responsive	572			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib + Panitumumab	BRAF (V600E)	Responsive	573			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Nvp + Dactolisib + Gdc + 0879	BRAF (V600E)	Responsive	574			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Gsk	BRAF (V600E)	Responsive	575			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib	BRAF (V600E)	Responsive	576			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Any cancer type	CANCER	BRAF MUT (G469A)	only gene	YES	Vemurafenib	BRAF-WASFL fusion	Responsive	577	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Breast adenocarcinoma	BRCA	BRAF MUT (G469A)	only alteration type	YES	Sorafenib	BRAF (G464V)	Responsive	578	627	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib + Cetuximab	BRAF (V600)	Responsive	579			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Lagerhans cell histiocytosis	HISLC	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600)	Responsive	580	203	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Trametinib + Dabrafenib	BRAF (V600)	Responsive	581			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	N-(1-Benzyl-2 + 3-Dihydroxy-4-{3-Methyl-2-[2-(2-Methyl-Propane-2-Sulfonylmethyl)-3-Naphthalen-1-Yl-Propionylamino]-Butyrylamino}-5-Phenyl-Pentyl)-3-Methyl-2-[2-(2-Methyl-Propane-2-Sulfonylmethyl)-3-Naphthalen-1-Yl-Propionylamino]-Butyramide	BRAF (V600)	Resistant	582			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only alteration type	YES	Afatinib	ERBB2 (G776L)	Responsive	611			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Head an neck squamous	HNSC	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib	ERBB2 (V773A)	Responsive	612			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Akti-1/2	ERBB2 amplification	Responsive	613			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Afatinib + Lapatinib + Trastuzumab	ERBB2 amplification	Responsive	614			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib + Trastuzumab	ERBB2 amplification	Responsive	615			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	Cetuximab + Oxaliplatin + Capecitabine	ERBB2 amplification	Resistant	616			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Uterine corpus endometroid carcinoma	UCEC	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab	ERBB2 amplification	Responsive	617			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	Cetuximab	ERBB2 amplification	Resistant	618			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Tyrphostin Ag 1296 + As602868	FLT3 (D835V)	Responsive	625			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute lymphoblastic leukemia	ALL	FLT3 MUT* (D835-)	only gene	YES	Sunitinib	FLT3 overexpression	Responsive	626			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Sorafenib	FLT3 (D835.,D835H)	Resistant	627			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Any cancer type	CANCER	KIT MUT (Y553N)	only alteration type	YES	Imatinib	KIT (N822H,V560G)	Resistant	632			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Chronic myeloid leukemia	CML	KIT MUT (Y553N)	only alteration type	YES	Bosutinib Monohydrate	KIT (V654A,V560G,D816H)	Responsive	633			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Acute myeloid leukemia	AML	KIT MUT (Y553N)	only alteration type	YES	Imatinib Mesylate	KIT (D816H)	Resistant	634			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	only alteration type	YES	Imatinib	KIT (V559D,L576P,V560G)	Responsive	635			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Gastrointestinal stromal	GIST	KIT MUT (Y553N)	complete	YES	Pictilisib + Imatinib	KIT oncogenic mutation	Responsive	636			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Prostate adenocarcinoma	PRAD	PTEN MUT (R335*)	complete	YES	Enzalutamide + Alpelisib + Azd8186	PTEN oncogenic mutation	Responsive	663			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Breast adenocarcinoma	BRCA	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Fulvestrant + Everolimus	PTEN expression	Resistant	664			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Glioma	G	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Egfr	PTEN expression	Responsive	665			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Thyroid papillary	THP	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Larotrectinib + 292	RET fusion	Responsive	666			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Lung	L	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Larotrectinib + 292	RET fusion	Responsive	667			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Any cancer type	CANCER	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Larotrectinib + 292	RET fusion	Responsive	668			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Non-small cell lung	NSCLC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Nintedanib	RET (CCDC6-RET)	Responsive	669			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Everolimus + Vandetanib	RET (KIF5B-RET)	Responsive	670			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Breast adenocarcinoma	BRCA	TP53 MUT (R249G)	complete	YES	Doxorubicin	TP53 (R175H,.,R249.)	Responsive	671			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Non-small cell lung	NSCLC	TP53 MUT (R249G)	complete	YES	Docetaxel	TP53 oncogenic mutation	Resistant	672			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Stomach	ST	TP53 MUT (R249G)	complete	YES	Chemotherapy	TP53 oncogenic mutation	Responsive	673			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Breast adenocarcinoma	BRCA	TP53 MUT (R249G)	complete	YES	Tamoxifen	TP53 oncogenic mutation	Resistant	674			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Leukemia	LK	TP53 MUT (R249G)	only alteration type	YES	Unii-Q8Mi0X869M	TP53 wildtype	Responsive	675			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Sarcoma	S	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK (RANBP2-ALK)	Responsive	681	165	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Sarcoma	S	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Crizotinib	ALK (F1174L)	Resistant	682			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Anaplastic large cell lymphoma	ALCL	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK (NPM-ALK)	Responsive	683	165	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Lorlatinib	ALK (EML4-ALK C1156Y)	Responsive	684			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Nvp-Auy922 + Ceritinib + Crizotinib	ALK (EML4-ALK C1156Y)	Resistant	685			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Tae684	ALK (F1174L,R1275Q)	Responsive	686			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Any cancer type	CANCER	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Ceritinib	ALK (EML4-ALK S1206Y)	Responsive	687			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (V1180L)	complete	YES	Tae684	ALK (EML4-ALK V1180L)	Responsive	688			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Ipi + 504	ALK fusion	Responsive	689			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Breast adenocarcinoma	BRCA	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	690	165	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Ceritinib	ALK fusion	Responsive	691			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Pemetrexed	ALK fusion	Responsive	692			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Anaplastic large cell lymphoma	ALCL	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	693	165	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Sarcoma	S	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	694	165	Resistant	B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Difuse large B Cell lymphoma	DLBCL	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	695	165	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Lung adenocarcinoma	LUAD	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Crizotinib	ALK fusion	Responsive	696	165	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Cutaneous melanoma	CM	ERBB3 MUT (V104M)	only gene	YES	Pertuzumab	ERBB3 overexpression	Responsive	711			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Uveal melanoma	UVM	ERBB3 MUT (V104M)	only gene	YES	Selumetinib + Trametinib	ERBB3 overexpression	Resistant	712			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only gene	YES	Av-203	ERBB3 expression	Responsive	713			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Pancreas adenocarcinoma	PAAD	ERBB3 MUT (V104M)	only gene	YES	9F7 + Chlorure De 1 Phenyle De Pyridine 4-Aldoxime [French] + Pertuzumab	ERBB3 expression	Responsive	714			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Head an neck squamous	HNSC	FGFR1 MUT (N577K)	only gene	YES	Nvp-Bgj398	FGFR1 expression	Responsive	717			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Chronic myeloproliferitve neoplasm	CMP	FGFR1 MUT (N577K)	only gene	YES	Midostaurin	FGFR1 (ZNF198-FGFR1)	Responsive	718			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Lung squamous cell	LUSC	FGFR1 MUT (N577K)	only gene	YES	219580-11-7	FGFR1 amplification	Responsive	719			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Breast adenocarcinoma	BRCA	FGFR1 MUT (N577K)	only gene	YES	1-{4-[(2-Chloro-5-{1-[3-(4-Cyclopropylpiperazin-1-Yl)Propyl]-5-(Methylsulfonyl)-4 + 5 + 6 + 7-Tetrahydro-1H-Pyrazolo[4 + 3-C]Pyridin-3-Yl}Phenyl)Ethynyl]Phenyl}-N-[(4-Chlorophenyl)Methyl]Methanamine	FGFR1 amplification	Responsive	720			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Breast adenocarcinoma	BRCA	ERBB3 MUT (V104M)	only gene	YES	Lapatinib	ERBB3 overexpression	Responsive	792			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Colorectal adenocarcinoma	COREAD	FGFR1 MUT (N577K)	only gene	YES	Nvp-Bgj398	FGFR1 expression	Responsive	797			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Bladder	BLCA	FGFR1 MUT (N577K)	only gene	YES	Dovitinib + 219580-11-7	FGFR1 expression	Responsive	798			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Lung	L	FGFR1 MUT (N577K)	only gene	YES	Ponatinib	FGFR1 expression	Responsive	799			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Non-small cell lung	NSCLC	FGFR1 MUT (N577K)	only gene	YES	Nvp-Bgj398	FGFR1 amplification	Responsive	800			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Uveal melanoma	UVM	GNAQ MUT* (Q209L)	only alteration type	YES	391210-10-9 + Sotrastaurin Acetate	GNAQ oncogenic mutation	Responsive	806			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
input01	Uveal melanoma	UVM	GNAQ MUT* (Q209L)	only alteration type	YES	1268524-70-4	GNAQ oncogenic mutation	Responsive	807			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
input01	Cutaneous melanoma	CM	GNAQ MUT* (Q209L)	only alteration type	YES	Vemurafenib	GNAQ (Q209P)	Resistant	808			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Trametinib	BRAF (PPFIBP2-BRAF)	Responsive	825			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Malathion	BRAF (L597S)	Responsive	826			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	complete	YES	Erlotinib	BRAF (G469A)	Resistant	827			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Sorafenib	BRAF (V600E)	Resistant	828			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib	BRAF (V600E)	Responsive	829			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Plx-4720 + Gdc-0941	BRAF (V600E)	Responsive	830			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Dasatinib	BRAF (V600E)	Resistant	831			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Pilocityc astrocytoma	PIA	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib	BRAF (V600E)	Responsive	832	203	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib	BRAF (V600E)	Responsive	833			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib + Cobimetinib	BRAF (V600E)	Responsive	834			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Digestive system	DS	BRAF MUT (G469A)	only alteration type	YES	Dabrafenib + Trametinib + Vemurafenib	BRAF (V600E)	Responsive	835			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Any cancer type	CANCER	BRAF MUT (G469A)	only alteration type	YES	Cobimetinib	BRAF (V600E)	Responsive	836			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Sorafenib	BRAF (G469E,V600E)	Responsive	837	627	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Trametinib + Dabrafenib	BRAF (V600.,V600E)	Responsive	838			A	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Sorafenib	BRAF (AGK-BRAF)	Responsive	839	627	Resistant	C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Hepatic carcinoma	HC	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib	ERBB2 (H878Y)	Responsive	857			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Stomach	ST	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib	ERBB2 (T862A)	Responsive	858			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colon carcinoma	COC	ERBB2 MUT* (G776A)	only alteration type	YES	Trastuzumab + Lapatinib + Neratinib	ERBB2 (V842I)	Responsive	859			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Uterine corpus endometroid carcinoma	UCEC	ERBB2 MUT* (G776A)	only gene	YES	Afatinib	ERBB2 amplification	Responsive	860			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	1166227-08-2	ERBB2 amplification	Responsive	861			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Palbociclib	ERBB2 amplification	Responsive	862			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Colorectal adenocarcinoma	COREAD	ERBB2 MUT* (G776A)	only gene	YES	Cetuximab + Panitumumab	ERBB2 amplification	Resistant	863			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Solid tumors	SOLID	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab	ERBB2 amplification	Responsive	864			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Non-small cell lung	NSCLC	ERBB2 MUT* (G776A)	only gene	YES	Dacomitinib	ERBB2 amplification	Responsive	865			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Quizartinib	FLT3 (D835V)	Responsive	869			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Daunorubicin + Sunitinib	FLT3 (D835V)	Responsive	870			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	only alteration type	YES	Cytarabine + Sunitinib	FLT3 (D835V)	Responsive	871			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Su-5614	FLT3 (D835)	Resistant	872			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Any cancer type	CANCER	KIT MUT (Y553N)	only alteration type	YES	Dasatinib	KIT (T670I)	Resistant	875			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Any cancer type	CANCER	PTEN MUT (R335*)	complete	YES	Ipatasertib	PTEN oncogenic mutation	Responsive	885			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Glioma	G	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Dacomitinib	PTEN expression	Responsive	886			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Any cancer type	CANCER	TP53 MUT (R249G)	only alteration type	YES	Cisplatin	TP53 (P47S)	Resistant	887			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Any cancer type	CANCER	TP53 MUT (R249G)	only alteration type	YES	Nutlin-3	TP53 wildtype	Responsive	888			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Any cancer type	CANCER	TP53 MUT (R249G)	only alteration type	YES	Amgmds3	TP53 wildtype	Responsive	889			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Colorectal adenocarcinoma	COREAD	TP53 MUT (R249G)	only alteration type	YES	Oxaliplatin + Capecitabine + Cetuximab	TP53 wildtype	Responsive	890			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	complete	YES	Ceritinib	ALK oncogenic mutation	Responsive	894			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Lorlatinib	ALK (EML4-ALK)	Responsive	895			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Any cancer type	CANCER	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Erlotinib	ALK (EML4-ALK)	Resistant	896			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Brigatinib	ALK fusion	Responsive	897			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Endometrial adenocarcinoma	EDA	KIT MUT (Y553N)	only gene	YES	Imatinib	KIT expression	Responsive	901			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Cutaneous melanoma	CM	KIT MUT (Y553N)	only alteration type	YES	Imatinib	KIT (D820Y)	Resistant	902			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Systemic mastocytosis	SM	KIT MUT (Y553N)	only alteration type	YES	Midostaurin	KIT (D816V)	Responsive	903			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Neuroblastoma	NB	ALK MUT (F1245C), ALK MUT (V1180L)	only alteration type	YES	Alectinib	ALK (F1174L)	Responsive	923	399	Resistant	D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (F1245C), ALK MUT (V1180L)	only gene	YES	Alvespimycin + Crizotinib	ALK (EML4-ALK)	Responsive	924			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Non-small cell lung	NSCLC	ALK MUT (V1180L)	complete	YES	Brigatinib	ALK (EML4-ALK V1180L)	Responsive	925			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1/summary
input01	Colorectal adenocarcinoma	COREAD	ARAF MUT (S217F)	only alteration type	YES	Irinotecan + Cetuximab + Vemurafenib	ARAF (S490T)	Resistant	927			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/3/summary
input01	Sarcoma	S	BRAF MUT (G469A)	only gene	YES	Temsirolimus + Bevacizumab + Sorafenib	BRAF (KIAA1549-BRAF)	Responsive	931			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Capecitabine + Vemurafenib + Bevacizumab	BRAF (V600E)	Responsive	932			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Vemurafenib + Cetuximab + Irinotecan	BRAF (V600E)	Responsive	933			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only alteration type	YES	Selumetinib	BRAF (V600E)	Responsive	934			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Glioma	G	BRAF MUT (G469A)	only alteration type	YES	Selumetinib	BRAF (V600E)	Responsive	935			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Colorectal adenocarcinoma	COREAD	BRAF MUT (G469A)	only alteration type	YES	Sorafenib + Cetuximab	BRAF (V600E)	Responsive	936			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Ovary serous	OVSE	BRAF MUT (G469A)	only gene	YES	2-Butanone	BRAF (BRAF-CUL1)	Responsive	937			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Non-small cell lung	NSCLC	BRAF MUT (G469A)	only alteration type	YES	Trametinib + Dabrafenib	BRAF (G596C)	Responsive	938			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Trametinib	BRAF (PAPSS1-BRAF)	Responsive	939			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Vemurafenib	BRAF (PAPSS1-BRAF)	Resistant	940			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Cutaneous melanoma	CM	BRAF MUT (G469A)	only gene	YES	Vemurafenib	BRAF (AGK-BRAF)	Resistant	941			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/5/summary
input01	Ovary	OV	ERBB2 MUT* (G776A)	only alteration type	YES	Lapatinib	ERBB2 (N857S)	Responsive	952			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Bladder	BLCA	ERBB2 MUT* (G776A)	only alteration type	YES	Platinum	ERBB2 oncogenic mutation	Responsive	953			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Ado + Trastuzumab	ERBB2 overexpression	Responsive	954			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Endometrial adenocarcinoma	EDA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab	ERBB2 amplification	Responsive	955			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Small cell lung	SCLC	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Irinotecan	ERBB2 amplification	Responsive	956			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Lapatinib + Capecitabine	ERBB2 amplification	Responsive	957			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Pancreas adenocarcinoma	PAAD	ERBB2 MUT* (G776A)	only gene	YES	Afatinib	ERBB2 amplification	Responsive	958			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Afatinib + Trastuzumab	ERBB2 amplification	Responsive	959			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	Trastuzumab + Capecitabine	ERBB2 amplification	Responsive	960			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ERBB2 MUT* (G776A)	only gene	YES	221	ERBB2 amplification	Responsive	961			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Lung adenocarcinoma	LUAD	ERBB2 MUT* (G776A)	only gene	YES	Gefitinib + Erlotinib	ERBB2 amplification	Resistant	962			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/20/summary
input01	Breast adenocarcinoma	BRCA	ESR1 MUT (E380Q)	only gene	YES	Palbociclib + Letrozole	ESR1 overexpression	Responsive	963			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/21/summary
input01	Acute myeloid leukemia	AML	FLT3 MUT* (D835-)	complete	YES	Quizartinib + Sorafenib	FLT3 (D835)	Resistant	968			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/24/summary
input01	Lung adenocarcinoma	LUAD	GATA2 MUT (R398W), GATA2 MUT (T354M)	only gene	YES	Fasudil + Bortezomib	GATA2 expression	Responsive	969			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/25/summary
input01	Any cancer type	CANCER	KIT MUT (Y553N)	only alteration type	YES	Imatinib	KIT (N822K)	Responsive	971			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Leukemia	LK	KIT MUT (Y553N)	only alteration type	YES	Imatinib	KIT (M541L)	Responsive	972			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Non-small cell lung	NSCLC	KIT MUT (Y553N)	only alteration type	YES	Nilotinib + Imatinib + Dasatinib	KIT (L576P)	Responsive	973			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/29/summary
input01	Head an neck	HNC	PTEN MUT (R335*)	complete	YES	Pictilisib + N-Alpha-L-Acetyl-Arginine	PTEN oncogenic mutation	Responsive	979			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Glioma	G	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Gefitinib + Erlotinib	PTEN expression	Responsive	980			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Breast adenocarcinoma	BRCA	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Trastuzumab	PTEN expression	Responsive	981			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Prostate adenocarcinoma	PRAD	PTEN MUT* (K267X), PTEN MUT (R335*)	only gene	YES	Everolimus	PTEN deletion	Responsive	982			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/41/summary
input01	Renal papillary cell	RPC	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Sunitinib	RET overexpression	Responsive	983			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Thyroid medullary	THM	RET MUT (M918T)	complete	YES	Axitinib	RET (C634W,M918T)	Resistant	984			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Thyroid medullary	THM	RET MUT (M918T)	complete	YES	Motesanib	RET (C634W,M918T)	Resistant	985			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Lung adenocarcinoma	LUAD	RET MUT* (DVYE898-901-), RET MUT (M918T)	only gene	YES	Vandetanib	RET (KIF5B-RET)	Responsive	986			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/42/summary
input01	Ovary	OV	TP53 MUT (R249G)	only gene	YES	Carboplatin + Cisplatin	TP53 overexpression	Resistant	987			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Ovary	OV	TP53 MUT (R249G)	only alteration type	YES	Cisplatin + Carboplatin	TP53 (Y234C,R273L)	Resistant	988			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Esophagous adenocarcinoma	ESA	TP53 MUT (R249G)	only alteration type	YES	Chemotherapy	TP53 wildtype	Responsive	989			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Non-small cell lung	NSCLC	TP53 MUT (R249G)	only alteration type	YES	Adjuvant Chemotherapy	TP53 wildtype	Responsive	990			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/45/summary
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	complete	YES	5-Iminopentanamide + Enzalutamide	AR (F877L)	Resistant	1030			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/67/summary
input01	Prostate adenocarcinoma	PRAD	AR MUT (F877L)	only alteration type	YES	Bicalutamide	AR (W742)	Resistant	1031			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/67/summary
input01	Colorectal adenocarcinoma	COREAD	ERBB3 MUT (V104M)	only gene	YES	Cetuximab	ERBB3 overexpression	Resistant	1039			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Any cancer type	CANCER	ERBB3 MUT (V104M)	only gene	YES	Selumetinib + Afatinib	ERBB3 overexpression	Responsive	1040			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1733/summary
input01	Sarcoma	S	FGFR1 MUT (N577K)	only gene	YES	Nvp-Bgj398 + Azd4547 + Tyrosine	FGFR1 expression	Responsive	1042			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Breast adenocarcinoma	BRCA	FGFR1 MUT (N577K)	only gene	YES	Ponatinib	FGFR1 amplification	Responsive	1043			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Bladder	BLCA	FGFR1 MUT (N577K)	only gene	YES	1-{4-[(2-Chloro-5-{1-[3-(4-Cyclopropylpiperazin-1-Yl)Propyl]-5-(Methylsulfonyl)-4 + 5 + 6 + 7-Tetrahydro-1H-Pyrazolo[4 + 3-C]Pyridin-3-Yl}Phenyl)Ethynyl]Phenyl}-N-[(4-Chlorophenyl)Methyl]Methanamine	FGFR1 amplification	Responsive	1044			C	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Breast adenocarcinoma	BRCA	FGFR1 MUT (N577K)	only gene	YES	4-Hydroxytamoxifen	FGFR1 amplification	Resistant	1045			D	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/1885/summary
input01	Uveal melanoma	UVM	GNAQ MUT* (Q209L)	only alteration type	YES	Trametinib	GNAQ oncogenic mutation	Responsive	1049			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
input01	Uveal melanoma	UVM	GNAQ MUT* (Q209L)	complete	YES	Selumetinib	GNAQ (Q209)	Responsive	1050			B	CIVIC	CIVIC: CIVIC=https://civicdb.org/genes/2317/summary
